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Hepatitis B is a major public health problem worldwide. The prevalence of hepatitis B is 
dependent on the modes in which it is transmitted. There are two common modes of hepatitis 
B virus (HBV) spread: vertical (mother to neonate) and the horizontal (via infected blood or 
body fluids). Chronic infection with HBV can progress to liver cirrhosis and liver cancer 
(hepatocellular carcinoma; HCC). Oman is regarded as an intermediate endemicity region 
and has had neonatal vaccine against HBV since 1990; however, little research has been 
conducted in Oman regarding risk factors for hepatitis B and its contribution to end stage 
liver disease and HCC. 
Aims 
 To identify the prevalence of major risk factors for acquiring hepatitis B in Omani 
patients currently infected with HBV (positive hepatitis B surface antigen (HBsAg)). 
 To estimate the contribution of hepatitis B to liver cirrhosis in Oman. 
Methods 
The prevalence of major risk factors was identified by interviewing HBsAg positive patients 
using a standard questionnaire. Patients were recruited from outpatient clinics at two tertiary 
referral hospitals in Oman’s capital city Muscat.  
Data on patients with liver cirrhosis admitted to two tertiary hospitals in Muscat over a period 
of seven years was abstracted from medical records. The diagnosis of cirrhosis was 
confirmed using defined criteria and the aetiology confirmed from the results of diagnostic 
tests including HBV serology. This data was analysed to estimate the contribution of HBV to 
cirrhosis in the cohort. 
Results  
For the first objective, 279 patients were interviewed. The number of male and female 
patients was similar, and 75.5% of the participants were aged 20 – 39 years. Antenatal 
screening was the most common means of detecting HBV infection in women and prior to 
blood donation was the most common means of identifying HBV infection in men. With 
respect to HBV transmission risk factors, intra-familial contact with HBV infected persons 
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and behavioural risks such as body piercing (females) and barber shaving (males) were more 
common than nosocomial risk factors. Knowledge about HBV infection was scarce among 
our participants. 
For the second objective, we identified records from 419 patients with cirrhosis. The median 
age was 59 years and males accounted for two thirds of the total studied population. 97.1% of 
patients were of Omani ethnicity. There was evidence of previous or current HBV infection 
(positive anti-bodies to hepatitis B core antigen) in 51.3% of the cirrhotic patients. 21.5% had 
active HBV (positive HBsAg).  Of the patients with current HBV 91.2% were infected with 
HBV alone while 8.8% were co-infected with hepatitis C virus (HCV).  Hepatitis C was 
present in 30.5% of cirrhotic patients and nearly half of those patients had evidence of past 
exposure to HBV. When stratified by gender, HBV infection was more common among male 
cirrhotic patients compared to females. 
Conclusions 
This study found that risk factors for HBV infection in Omani patients include direct contact 
of infected individuals within a family and exposure to high-risk behaviours such as piercing 
and barber shaving. Reducing vertical and horizontal transmission of hepatitis B in Oman 
could be improved by the implementation of routine antenatal screening of pregnant women 
and a greater focus on contact screening respectively. Future work is required to determine 
whether the association with behavioural risk factors is causal, particularly piercing and 
shaving at barber shops. If confirmed, relatively simple and effective interventions could be 
developed to reduce the risk of horizontal transmission related to these activities. 
We found that third of the patients identified with liver cirrhosis had past exposure to HBV 
and 20% had evidence of chronic infection. Most patients were of older age and male sex. 
This group of patients may benefit from antiviral therapy to prevent decompensation and 
regular surveillance for early diagnosis and treatment of HCC. Further research is required to 
assess the role of other exposures (alcohol, co-infection with other viruses) in the prognosis 
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1. CHAPTER ONE: INTRODUCTION 
This thesis reports on the studies to investigate aspects of the epidemiology of hepatitis B in 
Oman. There is currently little work in this area in Oman. Hepatitis B is an inflammation of 
the liver caused by the hepatitis B virus (HBV) and is a major global health problem. Almost 
2 billion people, that is 30% of the world’s population, have been infected with HBV and 350 
million are chronic carriers (Lavanchy, 2004). More than 75% of HBV cases are found in 
Asia, the Middle East and Africa (Andre, 2000). Oman is considered to be a country of 
intermediate endemicity for hepatitis B with 2-7% of the population being infected (Al-
Naamani et al., 2013). The hepatitis B vaccine was introduced to the Expanded Program on 
Immunization in 1990 with a reported coverage percentage of more than 98% for children 
less than one year of age in the year of 2012 (Sultanate of Oman Ministry of Health, 2012) 
HBV is mainly transmitted via blood and body fluid. There are two main modes by which 
HBV transmission occurs, vertical and horizontal. HBV transmission risk factors show 
substantial variation globally. Vertical transmission, i.e. from mother to child is the most 
common mode of transmission in high endemicity regions, which is responsible for most 
cases of chronic hepatitis B. Early horizontal transmission of HBV in children under the age 
of 5 years is thought to be the principal mode of transmission in the Middle East (Toukan, 
1990). Other common modes of transmission (late horizontal transmission) include unsafe 
medical settings, sexual contact (heterosexual or homosexual) and intravenous drug use 
(IDU) (World Health Organization, 2002).  Those mechanisms of spread are more common 
in low prevalence areas. 
According to the World Health Organisation, around 600,000 people die each year from 
hepatitis B related liver disease. More than 75% of HCC and liver cirrhosis cases in the 
Eastern Mediterranean Region are attributed to hepatitis B and hepatitis C infections (Perz et 
al., 2006). 
The thesis initially consisted of three main objectives. These were; (1) to estimate the 
incidence of acute hepatitis B (AHB) in Oman, (2) to identify the prevalence of major risk 
factors for acquiring HBV in Omani HBV positive patients and (3) to estimate the 
contribution of HBV to liver cirrhosis and HCC in Oman.  The first objective was to be 
initially achieved using data derived from reported cases of AHB in Oman and the published 
literature. However, this is likely to underestimate the real incidence and is discussed in 
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chapter three (see 3.4). Therefore I decided to abandon the first objective.. In relation to 
objective three, although HCC develops more commonly in patients with cirrhosis, patients 
with chronic hepatitis B (CHB) are at risk of developing HCC even in the absence of 
underlying cirrhosis. We initially aimed to investigate the role of HBV in both cirrhosis and 
HCC in Oman. However, there was another study being conducted to look at HCC and its 
aetiologies at the same time as I was conducting my study. Hence, objective three estimated 
the contribution of HBV to liver cirrhosis only.  
1.1 Overview of the thesis 
The remainder of this thesis consists of five chapters. Each chapter will look at the following; 
 CHAPTER 2 contains background information about Oman, the clinical features of 
hepatitis B and available preventive strategies. 
 CHAPTER 3 provides information derived from the literature regarding the 
epidemiology of hepatitis B, risk factors for the transmission of HBV and the current 
status of hepatitis B in Oman.  
 CHAPTER 4 investigates, in a cross sectional study, the prevalence of major risk 
factors for acquiring of HBV in Omani patients positive for HBsAg. 
 CHAPTER 5 attempts to estimate the contribution of HBV to liver cirrhosis in Oman 
by conducting a cross sectional study of medical records. 
 CHAPTER 6 summarizes the main findings of this research and lists the implications 




2 BACKGROUND, CLINICAL FEATURES AND PREVENTION OF 
HEPATITIS B 
2.1 Oman and health services 
The Sultanate of Oman is located in the southeast of the Arabian Peninsula. It is bordered by 
The Republic of Yemen to the southwest, the Kingdom of Saudi Arabia to the west and the 
United Arab Emirates to the north. Oman has an area of 309,500 square kilometers and a total 
population of 2,773,479 people of which 1,957,336 are Omanis and 816,143 are expatriates. 
Muscat is the capital city of Oman and it embraces about 28% of total population. The 
remainder are distributed between Al Batinah, Al Sharqiyah, Al Dakhliyah, and Dhofar 
(28%, 13%, 12% and 9% respectively) (figure 2.1). Oman has a young population with 55% 
of the population under the age of 19 (General Census of Population Housing & 
Establishments 2010, 2010). The official language is Arabic and Islam is the official religion. 
 




The World Bank classifies Oman as a high-income economy with an annual per capita 
national income of $12,476 or more. Before the year of 1970, there were only three schools 
in Oman with 909 students of whom all were males. However, under the ruling of His 
Majesty Sultan Qboos Bin Said, the government has invested in the educational sector to 
form a strong educational infrastructure. The illiteracy rate of people above the age of 15 has 
decreased from 41% in 1993 to 22% in 2003 (General Census of Population Housing & 
Establishments 2010, 2010).  
There has been an incredible advancement in the health sector in Oman with an increase of 
the number of hospitals from two with 12 beds and 10 clinics in 1970 to more than 50 
hospitals and 176 health centres run by the MoH distributed around the Sultanate by the year 
of 2010 (Sultanate of Oman Ministry of Health, 2010). Health care services are easily 
accessible and free of charge for all Omanis. 
The MoH is the main provider of health services in Oman. However, there are other health 
providers run by Ministry of Defence, Royal Oman Police (ROP), Petroleum Development 
Oman (PDO) and Sultan Qaboos University (SQU). Health services in Oman are available in 
two forms; hospitals and health centres. Hospitals include Governorate Hospitals that provide 
secondary and tertiary referrals, and Wilayat Hospitals that provide primary and secondary 
health services. Health centres on the other hand provide only primary outpatient services. 
All of these institutions serve people within their catchment area. The Muscat Governorate 
has more regional hospitals than any other region in Oman and they act as the national 
referral hospitals for cases from other regional hospitals. 
In the year of 2011, a total of 3,267,541 outpatient visits (including HBV cases) were made to 
regional hospitals, 46% of them were to health services other than MoH. The latter visits 
were mainly to the Armed Forces Hospital (AFH) and Sultan Qaboos University Hospital 
(SQUH) (49.7% vs 19.5% respectively) (Sultanate of Oman Ministry of Health, 2011). 
The AFH and SQUH are major regional hospitals in Muscat that provide secondary and 
tertiary health services to their employees and dependents. In addition, the SQUH provides 
care for the general population.  The AFH serves more than one third of the Omani 
population from different geographical regions (Al-Naamani et al., 2013).  
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2.2 Hepatitis B virus 
2.2.1 Structure 
The hepatitis B virus is classified within the family of hepadnavirus which solely infect 
hepatocytes. It is an enveloped virus measuring 42nm in diameter. The virus consists of 27nm 
isometric core and is surrounded by an outer coat of 4nm thickness. HBV contains a partially 
double stranded, circular 3.2 kb DNA genome consisting of four partly overlapping open 
reading frames (ORFs). ORF C encodes for the HBV core antigen and envelope antigen 
(HBcAg and HbeAg). ORF P encodes for the reverse transcriptase enzyme polymerase. ORF 
S encodes for the three forms of the HBsAg envelope protein (small, middle and large). 
Finally ORF X encodes for a transcriptional trans-activator protein needed for viral 
replication (Kramvis et al., 2005) (Neuveut et al., 2010). 
2.2.2 Genotypes 
There are 8 genotypes of HBV identified (A-H). The 8 genotypes differ in their length of 
open reading frames and the size of protein products translated. 
HBV genotypes have different geographical distributions. Genotype A is found mostly in 
North America, Northeast Europe and Africa. Genotypes B and C are mostly found in Asia 
and Oceania. Genotype D is found worldwide but predominantly in the Mediterranean region 
including Oman. Genotype E is most commonly found in the Western Coast of Africa and 
Madagascar on the East. Genotype F is found in aboriginal populations of South America. 
Genotype G is mainly found in France, Germany, United Kingdom, Italy and the United 
States of America. Lastly, genotype H is predominantly found in Amerindian populations of 
Central America, California and Mexico. There is also geographical variation in the 
distribution of HBV genotypes within countries such as in China, India and USA (Kramvis et 
al., 2005). 
It has been suggested that the different genotypes of HBV may have an effect on the progress 
of HBV related diseases. Studies found that genotype B is associated with less aggressive 
clinical course, early seroconversion of HBeAg with more sustained remission, decreased 
activity of necroinflammation in the liver, a slower rate of progression to cirrhosis and 
development of HCC compared to genotype C (Lok and McMahon, 2007, Lesmana et al., 
2006). In Japanese patients, genotype A has the highest chronicity rate compared to 
genotypes B and C (Yotsuyanagi et al., 2012). In India, genotype D is associated with more 
severe liver disease than genotype A (p<0.05) (Thakur et al., 2002). 
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The structural and functional differences between HBV genotypes may influence the 
response to treatment. When treated with interferon-alpha (IFN-α), genotypes A and B are 
associated with higher rate of HBeAg seroconversion compared to genotypes C and D (Lok 
and McMahon, 2007). Moreover, genotype C is thought to increase resistance to interferon 
therapy (Lesmana et al., 2006). 
2.3 Clinical Aspects of hepatitis B 
2.3.1 Clinical sequence of acute hepatitis B: 
This section is mostly based on a paper by Mitchell L. Shifman unless indicated otherwise. 
Development of acute hepatitis B is dependent on the age of infection and mode of 
transmission. Persons acquiring the infection perinatally are less likely to manifest acute 
infection compared to those acquiring the infection during adulthood (1% vs. 95% likelihood) 
(Goldstein et al., 2005). 
The human body can be susceptible to HBV transmission by either percutaneous or 
permucosal exposure. Percutaneous transmissions of HBV include transfusion of infected 
blood or blood products, organ transplant, use of contaminated needles, haemodialysis, cuts 
and playground injuries in childhood, tattooing and acupuncture. On the other hand, 
permucosal transmission of HBV results from homo/heterosexual activity and perinatal 
exposure (World Health Organization, 2002). 
Following the exposure, the virus circulates in the blood stream until it reaches the liver. The 
virus then enters hepatocytes by an unclear mechanism. The virus will then replicate in the 
hepatocytes leading to an increase in serum HBV DNA levels, and the expression of HBV 
proteins in the surface of infected hepatocytes (Shiffman, 2010). As a result, the immune 
response is initiated against the infected hepatocytes causing them injury. This is known as 
the incubation period where patients are usually asymptomatic with normal aspartate 
aminotransferase (AST) and alanine aminotransferase (ALT) levels. This period lasts for an 
average of 60 days; however, it may vary depending on the size of HBV inoculum, ability of 
antibodies to capture HBV, genetic variations and mode of transmission. At this stage, the 
serological markers appearing in the host’s serum are HBV DNA, HBsAg and HBeAg. 
The next period is the prodrome. At this stage, the levels of aminotransferases are elevated. 
The clinical presentation of patients in this period differs according to the age and immune 
status of the host. Infants, children and immune suppressed individuals are often completely 
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asymptomatic. On the other hand, adults develop non-specific symptoms such as malaise, 
anorexia, nausea, vomiting and abdominal pain. Such symptoms may last for a very short 
time of only 1-5 days and the diagnosis of HBV infection can be missed easily. Anti-HBc, 
HBsAg and HBeAg appear at this stage. 
The next phase is the icteric phase. This is defined as the onset of jaundice (bilirubin > 10 
mg/dL) approximately 90 days after infection. It is associated with appearance of dark urine, 
followed by pale stools and yellowish discoloration of the mucous membranes, conjunctivae, 
sclera and skin. It is important to note that not all acutely infected patients with HBV develop 
the icteric phase and it is mainly dependent on the age of infection. The risk of developing 
jaundice is 1%, 10% and 40% in neonates, children and adults respectively (figure2.2). This 
stage lasts for 4-12 weeks and is the stage where most cases seek medical care. Anicteric 
AHB is common in patients with human immunodeficiency virus (HIV), chronic renal failure 
on dialysis and patients with diabetes mellitus 
 
Figure 2.2 Relationship between the development of symptomatic acute icteric hepatitis, age and the likelihood of 
developing chronic HBV. 
Reference: (Shiffman, 2010) 
The last phase is the resolution stage. This stage is associated with a decrease in AST and 
ALT levels. It is also associated with disappearance of symptoms which is dependent on their 
severity. Patients who develop mild non-specific symptoms usually clear symptoms within 
few days, while those who develop acute jaundice, take weeks or months to clear the 
symptoms. Moreover, elimination of HBV DNA and seroconversion to anti-HBs, anti-HBe 

















dependent on the age and severity of the infection. Complete resolution is achieved in those 
with a short incubation period and who develop symptoms and jaundice. On the other hand, 
asymptomatic patients usually proceed to chronic infection. 
2.3.2 Natural history of chronic hepatitis B 
Information in this section is derived from two review articles by Fattovich et al and Neuveut 
et al (Fattovich et al., 2008) (Neuveut et al., 2010). CHB is defined as the failure to achieve 
seroconversion of HBsAg six months after infection with HBV. It occurs in 90%, 50% and 
10% of patients infected during infancy, early childhood and adulthood respectively.  
There are five phases of CHB; the immune tolerance phase, the immune active phase, the 
inactive HBV carrier phase, the HBeAg negative CHB and finally the HBsAg negative phase. 
The first stage is the immune tolerant phase. This stage is associated with positivity of 
HBeAg, raised levels of HBV DNA with normal or minimally elevated ALT. On histology, 
minimal liver damage is seen. This phase lasts for 1 to 3 decades in patients infected during 
infancy; however, it is much shorter in patients infected during childhood or adulthood. 
The second stage is the immune active, immune clearance or CHB phase. At this stage, 
immune cells attack infected hepatocytes. This leads to rise in serum ALT levels and 
continuous fall in HBV DNA levels. Moderate to severe liver necroinflammation is noted on 
liver histology which may progress to fibrosis.  Senescent hepatocytes are frequently found in 
patients at this stage of CHB which is believed to protect against malignancy. Patients 
presenting at this stage are usually infected during adulthood. 
The third phase is known as the inactive HBV carrier phase. At this stage seroconversion to 
HBeAg negative, anti-HBe positive is achieved. It is also characterized by normalization of 
ALT levels, low or undetected levels of HBV DNA and histological improvement of fibrosis 
and inflammation. 
The fourth phase is the reactivation phase (or, as in most cases, HBeAg negative chronic 
hepatitis B). Almost a third of patients from the previous stage will move into this stage. This 
is due to reactivation of HBV DNA by either spontaneous or immune suppression 
mechanisms. As a result, patients may return to the HBeAg positive state by reactivation of a 
wild type virus, or more commonly, reactivation of replication HBV variants that hinder the 
expression of HBeAg. Clinically, patients will have fluctuating levels of HBV DNA and 
ALT. On histology, active hepatitis with a variable amount of fibrosis is noted. 
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The final stage in the natural history of CHB is HBsAg negative stage. Only a small number 
of chronically infected patients (2% annually) will be able to lose the HBsAg and develop 
anti-HBs. This stage is associated with favourable prognosis of the disease. However, low 
levels of HBV DNA will remain detectable by PCR or liver biopsy. These patients will 
remain at risk of reactivation of hepatitis B whenever immunosuppressed. 
Table 2.1 Natural history of CHB 
HBeAg 
status 




















Low serum HBV DNA Low serum HBV 
DNA 
Fluctuating 
levels of HBV 
DNA 
 
Very low serum 
HBV 
ALT Normal serum 
ALT 
Raised serum ALT  Normal serum 
ALT  
Fluctuating 



















Note: data from (Neuveut et al., 2010) 
2.3.3 Diagnosis of HBV infection 
Serologically, the presence of HBsAg and anti-HBc class IgM indicates acute infection with 
HBV. On the other hand, chronic infection is diagnosed by the presence of HBsAg or by 
HBV DNA and anti-HBc class IgG for more than six months. The sole presence of anti-HBs 
indicates successful vaccination, whereas when accompanied with positive anti-HBc, it 
indicates immunity due to previous infection. 
Sometimes, an isolated anti-HBc is found in the blood (Lok and McMahon, 2007). This may 
be indicative of CHB where HBsAg has decreased to undetectable levels. This is common in 
high endemicity regions and in HBV patients co-infected with HIV or HCV. However, HBV 
DNA will remain detectable in liver. It can also be indicative of immunity where anti-HBs 
have fallen to undetectable levels, but anamnestic response can be observed after one dose of 
the vaccine in those patients. Another explanation is false positivity of anti-HBc. This is 
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common in individuals from low endemicity regions; however, they will respond to the 
vaccine similarly to those with no other HBV markers. Finally, during the window phase in 
acute hepatitis B, only anti-HBc is present in the serum but it should be of class IgM. 
2.3.4 Management of Hepatitis B 
Not all HBV positive patients require treatment. AHB is usually self-limiting and hence not 
treated with antiviral therapy. Patients with CHB on the other hand, are evaluated initially to 
decide on the appropriate treatment plan. Those with normal ALT respond poorly to current 
medicines and, therefore, are not considered for treatment. However, it is recommended that 
they have regular follow-up every 6 or 12 months to detect any changes in the disease status 
(Mohamed et al., 2004). 
 
Chronically infected patients with elevated ALT levels are treated to achieve suppression of 
HBV replication and remission of liver disease. The ideal aim is to prevent progression of the 
disease to cirrhosis, hepatic failure and HCC. Success of the treatment is evaluated by 
normalization of serum ALT, decrease in viral load (HBV DNA), loss of HBeAg with or 
without seroconversion to anti-HBe and histological improvement of the liver (Lok and 
McMahon, 2007). 
Antiviral therapies currently approved to treat hepatitis B are available in two forms; alpha 
interferon (α-IF) and Nucleos(t)ide Analogues (NUCs). Conventional α-IF is one of the drugs 
that are commonly used to treat chronic hepatitis B. It has a dual action of modulating the 
immune response and inhibiting the replication of HBV (Lavanchy, 2004). However, α-IF is 
associated with undesirable side effects, the painful route of administration of three weekly 
injections and high cost. The first NUC to become widely available is lamivudine. NUCs 
have the advantages of oral administration, reduced side effects and lower costs. However, 
resistance can develop with long-term treatment of more than 6-9 months, which limits the 
use of this NUC agent (Lavanchy, 2004). Subsequently a number of other NUCs have been 
developed to overcome the problem of resistance, and many of those are now available and 
approved for use (2012b). 
2.3.5 Progression to cirrhosis and HCC 
According to WHO, around 600,000 people die each year from hepatitis B related liver 
disease (Perz et al., 2006). HBV infection severity ranges from acute hepatitis with recovery 
and clearance of the virus from the host’s body, to progressive chronic disease leading to 
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cirrhosis of the liver and/or primary liver cancer.  Annually, 2-3% of chronic HBV carriers 
develop cirrhosis with a further 3% progressing to decompensated cirrhosis (Chen et al., 
2007). CHB is the major cause of HCC worldwide with more than half of HCC patients being 
chronic carriers. The risk of developing HCC in HBsAg patients is estimated to be 25-37 
times higher than non-infected people (Neuveut et al., 2010), with a 20% to 25% life time 
risk of death from HCC (Chen et al., 2007) 
There are several factors that are known to have a significant impact on the progression to 
cirrhosis and HCC. These include host, viral, clinical, lifestyle and environmental factors. 
The summary below is mainly derived from two review articles by Fattovich et al and 
McClune & Tong (Fattovich et al., 2008) (McClune and Tong, 2010). 
2.3.5.1 Host factors: 
Host dependent factors that influence the clinical outcome of CHB include age, gender and 
other factors such as region of origin and family history of HCC. Studies conducted in Asia 
and Western countries showed that the incidence of developing cirrhosis in HBV infected 
individuals increased significantly with increase in age, particularly over the age of 40 years. 
This can be attributed to the longer duration of disease exposure (Fattovich et al., 2008). As 
for developing HCC, cohort studies showed that patients aged 40-49 years are 3.6 to 5.4 
times more likely to develop HCC compared to younger patients (McClune and Tong, 2010). 
This risk increased to 8.3-17.7 in patients above the age of 60 years. 
Male gender is found to be an independent risk factor for cirrhosis. It is suggested that the 
antifibrogenic effect of oestrogen inhibits the activation of stellate cells and hence reduces the 
process of fibrosis (Fattovich et al., 2008). Male gender was also found to be a risk for 
developing HCC with an adjusted relative risk (ARR) of 2.1 (95 CI 1.3-3.3) and 3.6 (95% CI 
2.4-5.3) in men compared to women (McClune and Tong, 2010). Studies showed that the 
incidence of HCC in CHB patients per 100,000 person-years was almost three times higher in 
males in Taiwan, and up to five times higher in males in the USA (Nguyen et al., 2009).  
Studies from Eastern and Western regions show major differences in the incidence of 
cirrhosis and HCC. In high endemic regions such as Asia, HBV accounts for 70% of HCC 
cases (except for Japan 11%) (McClune and Tong, 2010). In low endemicity regions with 
increased numbers of immigrants from Asia, 70% to 80% of HBV induced HCC patients are 
of Asian ethnicity (Nguyen et al., 2009). In the USA, Asians develop HCC at a rate two times 
that of African Americans and four times that of Caucasians (McClune and Tong, 2010). 
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Individuals with a family history of HCC are more likely to progress to HCC from hepatitis 
B. This is noticed more in first degree relatives especially siblings (McClune and Tong, 
2010). This could be related to exposure. It may also suggest a role of genetic predisposition 
which is still under study (Fattovich et al., 2008). 
2.3.5.2 Hepatitis B Viral Factors 
HBeAg 
The risk of developing cirrhosis in patients with HBeAg positive chronic hepatitis ranges 
from 0.5 per 100 person years in immune tolerant patients with normal ALT levels to 3 per 
100 persons years in immune clearance patients with elevated ALT levels (Fattovich et al., 
2008). This is because patients in the immune tolerance phase have minimal or no liver 
damage and fibrosis; however, progression to the immune active phase is associated with 
moderate to severe liver necroinflamation and hence increased rate of fibrosis (Fattovich et 
al., 2008) (Neuveut et al., 2010). 
Patients with HBeAg negative chronic hepatitis were found to have almost two times the risk 
of developing cirrhosis of those with positive HBeAg status. This is because HBeAg 
seroconversion occurs at a later stage in the natural history of CHB; therefore, patients with 
HBeAg negativity had a longer duration of the infection (Fattovich et al., 2008). Moreover, 
HBeAg negative chronic hepatitis is associated with mutations in the pre-core and basal core 
promoter regions of the HBV genome which prevent the expression of circular HBeAg and 
increase the risk for cirrhosis and HCC (Neuveut et al., 2010). 
HBV DNA 
Increased levels of viral load were one of the strongest independent predictors of cirrhosis 
development and an independent predictor of HCC even after adjusting for known co-
variants (Chen et al., 2007).  Participants with HBV DNA levels between 300 and less than 
10,000 copies/mL were two times more likely to progress to cirrhosis compared with those 
who had HBV DNA levels below 300 copies/mL. Overall, HBV DNA of more than 10,000 
copies/mL was associated with significant increased risk for progression to cirrhosis and 




HBV genotypes affect the outcome of the HBV infection differently. For instance, genotype 
C is associated with a lower rate of spontaneous HBeAg seroconversion, hence prolonging 
HBV replication duration. This is associated with more severe hepatitis activity which may 
increase the risk of cirrhosis compared to those with genotype B (Fattovich et al., 2008). 
However, genotype B is found to be associated with earlier development of HCC in patients 
younger than 50 years and those who are not cirrhotic (Kao* et al., 2000). Genotype D is 
more prevalent in subjects with cirrhosis, suggesting more severe liver diseases and 
subsequent development of HCC (McClune and Tong, 2010). 
2.3.5.3 Clinical factors: 
Co- infections with other viruses affect the progression of CHB to cirrhosis or HCC. In 
addition, established cirrhosis increases the risk of HCC development. 
Hepatitis C virus (HCV) co-infection 
Dual infection of HBV and HCV alters the prognosis of the disease. This situation is not 
uncommon as it has been estimated that10-15% of CHB patients are co-infected with HCV 
(Fattovich et al., 2008). This is, as expected, more noted in areas with high prevalence of 
HCV and HBV infections. One cohort study from Taiwan found a significant association 
between developing cirrhosis and dual infection of HBV and HCV (Liaw et al., 2004). CHB 
patients who get acute HCV superinfection were 3.3 times more likely to develop cirrhosis 
than those infected with HBV alone. 
Studies conducted in Western and East Asian regions demonstrated an increase in the risk of 
developing HCC in patients with dual HBV and HCV infection compared to those with only 
HBV infection by 2-fold (Fattovich et al., 2008). 
Hepatitis D virus (HDV) co-infection 
HDV co-infection also impacts the outcome of HBV infection. It is estimated that 5% of 
HBV carriers worldwide are co-infected with HDV, which is more common in South 
America and the Mediterranean basin (Fattovich et al., 2008). 
Patients who are infected with both HBV and HDV had a roughly 3-fold increased risk of 
developing cirrhosis and HCC compared to those infected with HBV alone. 
Human Immunodeficiency virus (HIV) co-infection 
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The prevalence of HBV infection among HIV infected people ranges from 5-30% with it 
being more prevalent in Asia and parts of sub-Saharan Africa (Fattovich et al., 2008). The 
risk of chronic hepatitis B carriage increases in patients with HIV (Rockstroh, 2003). 
Moreover, HBV and HIV co-infection is associated with higher HBV replicative activity and 
lower rate of spontaneous HBeAg seroconversion. As a result, progression to cirrhosis is 
accelerated and the rate of decompensated cirrhosis is raised; however, the rate of HCC is not 
affected (Fattovich et al., 2008).  
Cirrhosis 
The risk of developing HCC is higher in cirrhotic patients regardless of their geographical 
origin. This risk increases in people infected with HBV from Asia rather than from Western 
countries (Fattovich et al., 2008). This can be attributed to the acquisition of the infection at a 
younger age and hence the longer time of infection. Around 90% of HBV induced HCC have 
histologic evidence of cirrhosis (McClune and Tong, 2010). 
2.3.5.4 Lifestyle factors: 
Alcohol and Smoking 
Alcohol is a major factor and co-factor for the development of cirrhosis and HCC. When 
combined with HBV infection, the natural course of the disease is affected negatively. A 
study conducted in Japan found that HBV infected patients with history of alcohol intake of 
≥500Kg are 6.4 and 8.37 times more likely to develop cirrhosis and HCC respectively than 
those with alcohol intake history of <500Kg (Ikeda et al., 1998) (the calculation method of 
500kg alcohol history was not reported in the study, but it was assumed to reflect high 
alcohol consumption). In addition, the presence of  anti-HBc alone with negative HBsAg 
status in patients with alcoholic cirrhosis was significantly associated with a more severe 
clinical profile like jaundice, high values of bilirubin, prothrombin time (PT) and Model for 
End-Stage Liver Disease (MELD) score (Zhang, 2013). Moreover, anti-HBc was associated 
with higher risk for short-term mortality.  
Studies conducted in Taiwan showed conflicting results on the role of cigarette smoking on 
the outcome of CHB. A 1.5 fold increased risk for HCC in smokers compared to non-
smokers was found in one study while zero impact was reported when studying a larger 




Diabetes is considered an independent risk factor for the development of HCC regardless of 
the presence of HCV, HBV, alcoholic liver disease or cirrhosis (McClune and Tong, 2010). 
Similarly, BMI of 35-40 increases the mortality risk by 5-fold in HCC patients compared to 
normal BMI (McClune and Tong, 2010). 
2.3.5.5 Environmental risk factors: 
One of the environmental risk factors that increases the risk of HCC is aflatoxin. Alfatoxin is 
a carcinogen that affects the liver by ingestion of mouldy foods resulting from storage of 
various grains most commonly in sub-Saharan Africa and Southeast Asia (Montesano, 2011). 
It has been shown that the risk of HCC rises by 3-fold in males modestly exposed to aflatoxin 
(McClune and Tong, 2010). 
Table 2.2 Summary of the factors that affect the prognosis of CHB 
Factors associated with increased risk of HBV related cirrhosis and HCC 
Host  Male gender, age>40 yrs, Asian ethnicity, positive family 
history 
HBV  HBeAg negative CHB, HBV DNA> 10,000 copies/ mL, 
genotypes C and D. 
Clinical  Co-infection with HCV, HDV or HIV, cirrhosis. 
Lifestyle  Alcohol, metabolic syndrome. 




2.4 Prevention of Hepatitis B 
2.4.1 Hepatitis B vaccine 
WHO recommended in 1992 that all countries should vaccinate newborns, adolescents and 
high risk groups against HBV. This led 177 countries to include HBV vaccine to their 
universal immunization by the end of 2009. This has reduced the prevalence of HBV carrier 
state which is mainly associated with perinatal transmission, hence preventing the risk of 
developing HCC making this vaccine the world’s first cancer vaccine. Taiwan was one of the 
first countries to initiate universal immunization against HBV in July 1984 (Chen et al., 
2012). Table 2.3 shows the vaccination programs of different countries. 
Table 2.3 HBV vaccination programs in different countries 




Infant coverage (%) Catch-up vaccinations, and high 
risk groups 
Oman (1990)* at birth 0, 3, 7 months >95 (2005) Adolescents in schools  
Healthcare workers 
Contacts of HBV infected 
individuals  
Saudi Arabia (1989)^ At birth, 1, 5 months 85% All Saudi children at school entry 
Health care workers 
Haemodialysis patients 
China (1992)** 0, 1 and 6 months 70 (2001) Pre-school children 
Adolescents 
Healthcare workers 
Taiwan (1984)** 0, 1 and 6 months  Pre-school 
First graders 
All children <15 years of age 
Australia (1996)** 0, 2, 4, 6 or 12 months  Adolescents 
High-risk groups 
New Zealand (1987)** 0, 1 and 3 months 90 (2001) Children entering high school 
Since 2000 an adult catch-up 
program targeting high-risk groups 
(Maori, Pacific Islanders and 
Asians) 
At risk groups 
*(Sultanate of Oman Ministry of Health) 
**(Mohamed et al., 2004) 
^ (Abdo et al., 2012a) 
Catch-up vaccination of individuals born before the introduction of neonatal vaccination is 
implemented in some countries around the world. These strategies are found to be more 
beneficial in areas of lower endemicity, i.e where infection is mainly acquired among 
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adolescents and adults. However, in high endemicity countries, such campaigns are not 
recommended as infection is chiefly transmitted perinatally or during early childhood 
(Mohamed et al., 2004). 
Hepatitis B vaccine is safe in pregnant women at any stage of pregnancy, so pregnant women 
who have never been immunized against HBV and who are at risk of being infected should 
not be deterred from getting the three doses of vaccine. It is also safe and immunogenic in 
patients with mild-moderate liver disease (Yu et al., 2006) (Tran, 2012). 
2.4.2 Limitations and Challenges 
There are a number of limitations and challenges faced by the world in order to reach a full 
HBV vaccine coverage. Some of these challenges are discussed below. 
2.4.2.1 Compliance 
One of the challenges to effective immunization against hepatitis B is the compliance of 
vaccine recipients to the three-dose administered over a period of six months. In Turkey 
statistics suggested that 11% to 20% did not adhere to the HBV three-dose vaccine at age 0 
(OZER A et al, 2011). The reasons for noncompliance include socioeconomics factors such 
as older age, lower household income and lower educational levels which decreases 
awareness about the importance of having the hepatitis B vaccine (Park et al., 2012). 
However, such characteristics may have different effects in developed countries. In the USA, 
for example, the vaccination rate is found to be lower in infants born to mothers with a higher 
educational level, higher annual income and private insurance (O'Leary et al., 2012). 
Some have studied the use of a two-dose vaccine as an alternative which may enhance 
compliance to the immunization schedule. Halperin et al, for example, found while 
conducting a randomized observer blinded control trial that an alternative two-dose vaccine 
had a statistical superiority in seroprotection rate and magnitude of antibody response when 
compared to the three-dose licensed vaccine in 18-55 years of age (Halperin et al., 2012). 
2.4.2.2 Inadequate implementation of recommended prevention strategies 
Perinatal transmission of HBV is the predominant mode of transmission in high endemicity 
regions such as Asia and Africa which is responsible for most of the chronic cases and hence 
increasing the risk of developing cirrhosis and HCC. Therefore, antenatal screening of 
pregnant women for HBsAg is essential to identify new-borns who are at high risk of being 
18 
 
infected. The risk of transmission is increased by forty-fold in neonates of HBeAg positive 
mothers when compared to HBeAg negative mothers (Chen et al., 2012). 
Today there are three main immunoprophylaxic strategies against HBV implemented around 
the world. The first strategy is the active immunization using the three-dose hepatitis B 
vaccine only in all neonates. The second strategy is active immunization using the three-dose 
vaccine plus passive immunization by administering hepatitis B immunoglobulins (HBIG) to 
neonates born to HBsAg mother regardless of her HBeAg status. The third strategy is to 
actively and passively immunize neonates born to HBsAg and HBeAg positive mothers 
(Chen et al., 2012). 
Studies have shown that passive immunization with a single dose of hepatitis B immune 
globulins within the first 12 hours of birth in addition to the active immunization with three 
doses of intramuscular hepatitis B vaccine within 0, 1 month and 6 months respectively, 
would be a 90-100% effective in preventing the transmission of HBV in neonates born to 
CHB mothers (Hu et al., 2012). 
The recipient of hepatitis B vaccine in new-born nurseries is dependent on the hospital 
policies. The likelihood of receiving hepatitis B vaccine increases in birth institutes that have 
written policies to screen pregnant women for HBsAg and to offer vaccine against HBV to all 
new-borns compared to institutes that do not have such written policies (O'Leary et al., 2012). 
2.4.2.3 Effectiveness of the vaccine 
The effectiveness of active passive immunization was found to be 89.5% in children born to 
HBeAg positive mothers and 97.9% effective in children born to HBeAg negative mothers 
(Chen et al., 2012). 
A cohort study to assess the long term protection of hepatitis B vaccine in a high endemic 
region found that 78% of vaccine responders (i.e their anti HBs titre was >10 mIU/mL after 
primary vaccination at birth) had anti HBs titres below protective levels. However, 81% of 
those developed a rapid prominent increase in antibody levels after the administration of a 
Hepatitis B vaccine booster 10 years later. The anamnestic response was found to be 
dependent on mother’s past history of HBV infection, concentration of anti-HBs and time 
since primary vaccination. Offspring of carrier mothers are 2.43 times more likely to respond 
to the vaccine compared to offspring of non-carrier mothers (Schonberger et al., 2012). 
Moreover, children who have anti-HBs titre of >100mIU/mL are 2.8 times more likely to 
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have an anamnestic response compared to those who have a lower titre level (Chaves et al., 
2012). 
In adults the efficacy of the hepatitis B vaccine was evaluated in a high risk group of gay men 
in New York City, USA. The placebo-controlled, randomized, double blinded clinical trial 
found that 87% of vaccine recipients were responsive to the vaccine and developed anti-HBs 
after 3 months. The percentage increased to 96% after the administration of a booster 
injection. The concentration of the surface antigen antibodies (anti-HBs) remained unchanged 
18 months later (Szmuness et al., 1980). 
2.4.2.4 Intrauterine HBV infection  
Intrauterine HBV infection is the transplacental transmission of HBV that cannot be 
prevented by hepatitis B vaccine. The risk of transplacental transmission increases with the 
mothers’ HBeAg status. HBeAg positive mothers have a 70-90% risk of transmission without 
administration of prophylaxis. Those born to HBeAg positive mothers have 40.3-fold greater 
HBsAg rate than those born to HBeAg negative mothers (Chen et al., 2012) (Xu et al., 2002). 
The risk also depends on the concentration of HBsAg & HBV DNA titres in the pregnant 
woman. One study showed that active-passive immunoprophylaxis achieved 100% efficacy 
in children born to mothers with HBV DNA concentration of <150pg/mL. However, this has 
been reduced to 68% in children born to mothers HBV DNA concentration of >150pg/mL 
(del Canho et al., 1997). 
Other factors that increase the risk of intrauterine transmission include threatened preterm 
labour, HBV infection in villous capillary endothelial cells in placenta, transplacental leakage 
of maternal blood, exposure to cervical secretions and maternal blood during labor and 
delivery and specific allelic mutations in maternal blood (del Canho et al., 1997) (Tran, 
2012). 
Treatment of pregnant women remains controversial due to insufficient evidence on its safety 
and efficacy of preventing transmission.  Anti-viral therapy with lamivudine for pregnant 
women with abnormal ALT levels, positive for HBsAg and HBeAg, have HBV DNA 
≥1.0×107 copies/m, during the gestation period between 24-32 weeks, decreases intrauterine 
HBV infection along with the vaccine and immunoprophylaxis for the new-born babies (Yu 
et al., 2012). 
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2.4.3 Hepatitis B screening programs 
In spite of having an effective vaccine that reduces the prevalence of the HBV infection in 
children, time is needed to achieve a sufficient prevalence of immunity so that HBV can no 
longer spread. Therefore, HBV screening and treatment of high risk groups will add to the 
control of hepatitis B. 
Currently, offered screening programs include: antenatal screening of pregnant women in 
many countries, screening of ethnic groups (e.g. Maori, Pacific Islanders and Asians over the 
age of 15 years born before implementation of neonatal vaccine) for CHB and HCC in New 
Zealand, screening of children and adolescents before entering kindergarten or schools in 
China, and screening of people applying for a residential visa in Singapore (Mohamed et al., 
2004). Additional screening of STD clinic attendees may increase the control of HBV 
transmission in low endemicity regions (Goldstein et al., 2002) (van Duynhoven et al., 1997).  
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3 EPIDEMIOLOGY OF HEPATITIS B 
This section summarises the global epidemiology of HBV infection, then looking specifically 
at Oman. 
3.1 Search strategy for the literature review 
The starting point for this literature was the World Health Organization (WHO) publications 
on hepatitis B which give brief information regarding the clinical aspects, the epidemiology, 
the modes of transmission and the burden of the disease. Then, article databases were 
searched using the following terms; “HBV”, “hepatitis B”, “HepB”, “chronic”, “acute”, 
“genotype”, “epidemiology”, “incidence”, “prevalence”, “risk factors”, “transmission”, 
“family”, “IDU”, “blood transfusion”, “dialysis”, ‘surgery”, “piercing”, “barbers”, “shaving”, 
“burden”, “HCC”, “hepatocellular carcinoma”, “cirrhosis”, “liver fibrosis”, “outcome”, 
“HCV”, “alcohol”, “co-infection”, “prevention”, “treatment”, “vaccine”. Further research 
using more specific key words was conducted throughout the writing process. The data bases 
searched were Ovid via Medline, PubMed, Scopus and Google Scholar. 
There was not much research of interest conducted in the Gulf Cooperation Council (GCC) 
or Arab countries; therefore, studies from the Middle Eastern countries such as Turkey, Iran 
and Pakistan were included for the purpose of comparison. Full text articles published in 
English were included. 
3.2 Global descriptive epidemiology of hepatitis B  
3.2.1 PERSON: 
Age 
The age at which hepatitis B occurs is dependent on the mode of transmission and determines 
the outcome of the disease (see 2.3.1). In areas where early horizontal transmission is more 
frequent, prevalence of HBV infection is lower in new-borns compared to young children. In 
Africa, for example, HBsAg positivity increases after the age of 6-12 months and the highest 
seroprevalence is found in children aged 3-5 years (Custer et al., 2004). Similarly, in Saudi 
Arabia in 1991, HBsAg was highest in children of 1 year of age with a positivity rate of 
9.7%, which decreases with age (Al-Faleh et al., 1992). 
Where adult horizontal transmission is mostly common, the incidence of HBV infection is 
found to be higher in young adults. In urban areas of South and Central America for example, 
22 
 
hepatitis B surface antigen is highest in the age group of 20-40 years and lowest in children 
under the age of 12 years. Findings from Eastern Europe are also consistent where HBsAg 
incidence is higher in persons aged 20-29. However, a different pattern is found in Western 
Europe where seroprevalence of HBsAg was found to be three times higher in persons older 
than 50 years compared to persons aged 25-35 years. This may suggest a decrease in 
horizontal transmission of HBV over time (Custer et al., 2004). In the United States, the 
incidence of acute hepatitis B decreased by 89% in the age group 0-19 years between 1990 
and 2002 (Centers for Disease and Prevention, 2004). The decline was also noted in the age 
groups 20-39 and ≥40 by percentages of 67% and 39% respectively from 1990 to1998. 
However, the incidence in the latter age groups increased after 1998 by 5% in males aged 20-
39 years, and 20% and 31% in males and females respectively older ≥40 years. 
Finally, in Egypt, all three types of transmission modes are evident. When comparing the 
North and South of Egypt, HBsAg seroprevalance is highest in teenagers aged 4-18 years and 
in adults aged 39-48 respectively (Custer et al., 2004). 
Gender 
Globally, HBsAg carriage is generally found to be higher in males than in females. When 
comparing the general population in Thailand, HBsAg is 1.7 times as high in males than in 
females, and three times as high among male blood donors compared to female blood donors 
(Custer et al., 2004). In Kuwait, the incidence of AHB is two times higher in males than in 
females (Toukan and Group, 1990). In the USA, the ratio of male to female HBsAg incidence 
was found to be 1.5 in 1990 and 1.7 in 2002 (Centers for Disease and Prevention, 2004). 
Moreover, there has been an overall decrease in HBV carriage rate which is noted more in 
females than males. This observation was also noted in countries in Africa, Western Pacific 
and Asia (World Health Organization, 2002). It is suggested that females are more likely to 
clear the HBV and develop antibodies against it (Al-Faleh et al., 1992). On the contrary, 
when studying Saudi children, no significant difference in HBsAg prevalence was noted 
between genders (Al-Faleh et al., 1992). 
Ethnicity 
Epidemiological studies have reported different distribution in the prevalence of hepatitis B 
by ethnic grouping. For example, this is noted in North America where higher prevalence of 
HBV infection in Native Alaskan, Ethnic and Native Canadian populations is reported. 
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Similarly, in areas of South and Central America, seroprevalence is higher in native 
populations (Custer et al., 2004). In New Zealand, the prevalence of chronic hepatitis B, by 
the year of 2002, was found to be 7.3% in Pacific Islanders, 6.2% in Asians, 5.6% in Maori 
and 2.8% in other ethnicities (Robinson et al., 2005). 
3.2.2 PLACE: 
HBsAg carriage prevalence shows geographical variations and ranges between 0.1 to 20% 
globally (Custer et al., 2004). WHO divides the world into three zones according to the 
prevalence of HBsAg carriage. The three zones are: low endemicity where the prevalence of 
carriage is <2% which includes North, West and Central Europe, North America, Australia 
and New Zealand; intermediate endemicity where carriage is 2-7% such as in Eastern Europe, 
Mediterranean, Russia and the Russian Federation, South-west Asia and Central and South 
America; and the high endemicity zone with a carriage of 7-15% such as parts of China, 
South East Asia, and Tropical Africa (World Health Organization, 2002) 
 
Figure 3.1 Geographical distribution of chronic hepatitis B. 
Reference: (World Health Organization, 2002) 
The Western Pacific region (except New Zealand, Australia and Japan) has the highest 
number of hepatitis B carriers with around 150 million chronically infected individuals 
(Lesmana et al., 2006).  Africa is the second highest region with 58 million chronically 
infected individuals (Custer et al., 2004) 
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Geographical differences in hepatitis B prevalence within a country are also noted. In Egypt 
for example, the prevalence of HBsAg was higher in Upper Egypt 11.7% than in Lower 
Egypt (8%), with 88% of these populations found to be positive for anti-HBc (Sherif et al., 
1985). This was also noted in Iran where positivity for HBsAg and anti-HBc was higher in 
rural areas compared to urban areas (OR 3.0, 95% CI 1.2-7.2, p= 0.01) (Merat et al., 2009). 
3.2.3 TIME: 
There has been a worldwide reduction in hepatitis B after the development of a vaccine in 
1982 (Lavanchy, 2004). Taiwan, for instance, was one of the first countries to initiate 
universal immunization against HBV in July 1984. Since then, the chronic HBV carrier rate 
has decreased from 10%-20% to 1%-2% (Chen et al., 2012). There also has been a reduction 
in the incidence of HCC by around 67% and the incidence of infantile fulminant hepatitis in 
Taiwan. 
Similar results were noted in Africa. HBsAg prevalence was significantly reduced in children 
in Gambia and Senegal from 10% to 6% and from 18.7%-2.2% respectively (Custer et al., 
2004). In addition, the age group of 15-24 in 1988 was compared to the same age group 6 
years later in Italy noting a reduction in AHB by half.  
In the United States, the incidence of AHB decreased by 67% over the time period of 1990-
2002 (Centers for Disease and Prevention, 2004), and by 88% over the time period of 1991-




3.3 Modes of transmission and risk factors 
There are two major modes by which HBV is transmitted. These are vertical and horizontal 
transmission. Transmission of HBV varies depending on the prevalence of HBsAg in each 
country. In hyper-endemic areas such as Southeast Asia and Western Pacific, perinatal 
transmission seems to be the major mode of HBV transmission. Intermediate endemicity of 
hepatitis B in areas such as the Middle East is attributed to early horizontal transmission of 
the virus in children of preschool age (Toukan and Group, 1990, Toukan, 1990). Horizontal 
transmission of hepatitis B in adults has been shown to be the main mode of transmission in 
low endemicity areas such as North America and Europe (Custer et al., 2004). The mode by 
which HBV is transmitted is a key aspect in determining the prognosis of the infection. The 
risk of developing CHB increases in patients who acquire the virus vertically or in early 
childhood (<5years).  
HBV is 100 times more infectious than HIV and can survive outside the human body for at 
least seven days. HBsAg has been found in most bodily secretions of infected individuals. 
These include blood, vaginal and menstrual fluids, semen, saliva, perspiration, breast milk 
and tears, each with a different infectivity risk (Lavanchy, 2004) (World Health Organization, 
2002). The risk of transmitting the virus is mainly dependent on the amount of the virus DNA 
in the serum, which is found higher in HBeAg positive patients (Shiffman, 2010). 
3.3.1 Vertical transmission 
Perinatal transmission of HBV is the predominant mode of transmission in high endemicity 
regions such as Asia and Africa. This mode is responsible for most of the chronic cases and 
hence increasing the risk of developing cirrhosis and HCC (more details in 2.4.2.4).  
In the Middle East, perinatal transmission of HBV is thought to play a secondary role in the 
endemicity of hepatitis B. When assessing the effect of mother to child transmission of HBV 
in Arab countries, HBsAg positivity appeared in 21% of infants born to HBsAg positive 
mothers (Toukan and Group, 1990) (Toukan, 1996). The majority of transmission occurred in 
mothers positive for HBeAg compared to mothers negative for HBeAg (94% vs. 10% 




3.3.2 Horizontal transmission 
3.3.2.1 Household contact and spousal transmission 
Household contact with HBV infected members is a common way of spreading HBV 
infection in areas with HBsAg endemicity of 2-7% such as the Middle East. It is affected by 
the characteristics of the household such as family size, number of infected individuals, their 
relationship, socio-economic status of the family and members’ serologic status. 
One study conducted by Toukan et al. in Jordan in 1990, found a 49% increase in HBsAg 
positivity rate in families consisting of more than six members when compared to families of 
2-5 members (p<0.01) (Toukan, 1990). A more recent study by Bawazir et al. showed 
supporting results where household size of 5-9 members are 2.9 more likely at risk of 
hepatitis B infection compared to smaller family size (AOR= 2.9, CI= 1.1-7.6) (Bawazir et 
al., 2011). Similarly, a study from Turkey showed a significant increase in the rate of HBV 
transmission in families with ≥5 members (p< 0.05) (Urganci et al., 2013). Transmission can 
be explained by shared use of intimate objects such as utensils, tooth brushes, bottles, toys, 
razors and other objects (Bawazir et al., 2011). 
Toukan et al. also reported that the prevalence of HBV infection rose from 57% to 98% in 
families when the number HBV carriers increased from 1 to 3 respectively (p<0.05) 
regardless of the size of the family (Toukan, 1990). 
One other feature that affects the transmission of HBV in a household is the relationship 
between the individuals. The prevalence of HBV carriage in children of an HBsAg positive 
mother was greater than those of HBsAg negative mothers; however, the HBsAg positivity of 
the father did not significantly increase the carriage rate in the children as that of the mother 
(Toukan, 1990). The reason why vertical transmission was not considered to be the mode of 
transmission was due to the low HBeAg positivity status in HBsAg mothers and women of 
child bearing age. Moreover, the authors found no child under the age of one to be positive 
for HBsAg, hence attributing the transmission to close mother to child contact compared to 
that with the father. Similarly, it was found that persons who live with an HBsAg positive 
parent are 3.25 more likely to get infected with HBV than those who live with HBsAg 
negative parents (95% CI: 1.73-6.12, p<0.05) (Ozer et al., 2011). 
Most of the contact reported above is described as intimate non-sexual contact. When trying 
to assess the role of spousal transmission of HBV, a case control study by Ozer Ali in Turkey 
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found that having an HBsAg positive spouse increases the risk of being infected by the virus 
by 4.3 times (95% CI: 2.12-8.53, P<0.05) with the risk being found higher in female patients 
compared to males, especially in patients <30 years. They also found that 61.2% of the 
women were likely to have acquired the virus from their positive partner (excluding sexually 
inactive and haemodialysis patients) (Ozer et al., 2011) 
3.3.2.2 Sexual activity 
Sexual activity is a major risk factor for acquiring AHB, mainly in Western societies where 
the prevalence of HBV is low (Custer et al., 2004). In the United States, heterosexual 
relationships with one infected partner or multiple partners accounts for 27.4% of acute 
hepatitis B infections, and homosexual relationships account for 13.5% of infections 
(Goldstein et al., 2002). Moreover, a study to measure the prevalence and risk factors for 
HBV infection among STD clinic visitors in the Netherlands found that HBV prevalence in 
STD clinic visitors is higher than the general population. They also found that the risk factors 
for current infection of HBV (HBsAg positive) were a history of STD and number of partners 
in the past half a year (inversely). The inverse association between HBsAg positivity and the 
number of partners in the past six months is contradictory to other studies. This is suggested 
to result from confounding by non-investigation regarding perinatal transmission mode as 
well as the inappropriate time frame to assess exposure to the virus. On the other hand, the 
risk factors for previous infection (HBcAg positive) were found to be commercial sex, 
number of lifetime partners, homosexual contact, orogenital contact (inverse) and history of 
STD. (van Duynhoven et al., 1997)  
3.3.2.3 IDU 
IDU is one of the most commonly identified risk factors for hepatitis B besides sexual 
activity in the regions of North America and Europe (Custer et al., 2004). It has been reported 
that 18.2% of AHB in the USA is attributed to IDU (Goldstein et al., 2002). The incidence of 
AHB in this high risk group has decreased by 90.6% over the period from 1988-1998, but this 
was accompanied with an increase in the age of IDU associated HBV transmission. 
The prevalence of HBV infections among injecting drug users in the Middle East varied 
considerably between countries. In Pakistan, a HBV prevalence of 6% was found in IDU risk 
group in the city of Quetta (Ali et al., 2009), while the prevalence of HBV among IDU in 
Ahvaz, Iran was as high as 44.3 % (Jahangirnezhad et al., 2011). 
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In Saudi Arabia HBV DNA was found to be positive in 12% of IDU, being ten fold higher 
than in the general population (1.7%) (Alzahrani et al., 2009).  
3.3.2.4 Health-care associated infections 
3.3.2.4.1 Unsafe injections 
Unsafe injections in health care settings are one of the ways HBV is transmitted in 
developing countries. It was suggested that 58% of HBV infection in the Eastern 
Mediterranean region is attributed to unsafe injections each year (World Health Organization, 
2009). This results from the reuse of infected, unsterilized needles in the health care settings. 
WHO estimates that the average person in Southeast Asia receives four injections annually, 
with the majority being unnecessary and three quarters unsafe or reused (Ali et al., 2009). In 
Pakistan, the attributable risk for therapeutic injections was found to be 53% in patients with 
AHB. The reason for the increased risk of HBV transmission via unsafe injections results 
from patients’ preference of injectable to oral medications, unawareness of some health care 
workers about the risk of transmitting blood borne pathogens via unsterile needles and 
financial limitations of some medical institutes. Another example is Moldova where 
injections in the healthcare setting are major source of HBV transmission as a result of the 
widespread reuse of inadequately sterilized single-use syringes (Ozer et al., 2011). 
3.3.2.4.2 Receipt of blood and blood products 
Blood transfusion is one of the most efficient modes of HBV transmission. Studies in Egypt 
found an association between blood transfusion and hepatitis B among patients with chronic 
haematological disorders in need of regular blood transfusion (Gasim et al., 2013). Similarly, 
in the time period of 1997 to 2009 in the USA, HBV was found to be 5.4% higher in patients 
with sickle cell disease (Nouraie et al., 2012). Patients with sickle cell disease were found to 
be 1.82 times more likely to have concurrent infection with HBV than patients without sickle 
cell disease (95% CI 1.24-2.68).  
3.3.2.4.3 Organ transplantations 
Organ transplantation is one of the routes in which HBV can be transmitted from an infected 
individual to a naïve recipient. The virus can be introduced to the body percutanously by 
either infected organs or blood products (Kennedy et al., 2005). 
The risk of viral infection increases among those undergoing commercial transplants, 
especially if it was conducted in a high endemicity region. For example, when comparing 
29 
 
Saudi patients who have undergone renal transplant in India to locally transplanted patients 
from the period of 1978-1993, it was found that the risk of acquiring hepatitis B viral 
infection was 6.7% higher when conducted abroad (8.1% vs. 1.4%) (Kennedy et al., 2005).  
3.3.2.4.4 Haemodialysis and other medical procedures 
Haemodialysis has been identified as a risk factor for the transmission of HBV. In Turkey, 
patients undergoing haemodialysis were found to be 8.32 times more at risk of HBV 
infection, especially in patients over the age of 31 (p<0.001) (Ozer et al., 2011). 
In Brazil, the prevalence of HBV infection was higher among haemodialysis patients 
compared to the general population (Neto et al., 1995). Treatment with haemodialysis 
(excluding transfusion of blood) significantly increased the risk of viral transmission. This 
indicates environmental transmission of the virus which was supported by a decrease in 
incidence with isolation of patients tested positive for the virus.  
In Asia-Pacific countries the incidence of HBV infection in haemodyalisis reflects the 
endemicity of the virus in that country. For example, in Japan where HBV endemicity is low, 
the incidence of HBV infection among haemodialysis patients was 1.3% compared to 14.6% 
in China which is a high endemic country (Johnson et al., 2009).  
Other medical procedures such as surgeries, endoscopy and dental interventions were 
identified as a risk factor for transmitting HBV. In a case control study in Iran, for example, 
history of major surgery and endoscopy was positive in 44% and 55% of participants 
respectively and were found to be independent risk factors for CHB infection 
(Jahangirnezhad, 2011). However, several studies from Arab and African countries failed to 
show any significant impact of surgical procedures, home deliveries and dental procedures 
(Gasim et al., 2013). 
3.3.2.5 Occupational risks  
An association has been established between HBV transmissions and some professions 
depending on the exposure to infected individuals. Examples of these professions include 
doctors, nurses, dentists, barbers, police men and sex workers. 
In Pakistan, health care workers were found to have a higher prevalence of HBV infection 
compared to the general population (6% weighted average) which is mainly caused by the 
lack of universal vaccination of high risk groups (Ali et al., 2009). A cross sectional study in 
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Iran in 2011 found that 5% of positive HBV carriers were nurses (Jahangirnezhad et al., 
2011). 
On the contrary, some studies found either low or no evidence of hepatitis B infection among 
HCW. This can be explained by their highest compliance rate with HBV vaccination program 
due to their exposure to recurrent informational activities about the disease (Ozer et al., 
2011). 
3.3.2.6 Others  
Other risk factors that are thought to contribute to the transmission of HBV include shaving 
with a barber, tattooing, piercing and acupuncture. These practices are expected to introduce 
the virus percutaneously to the body; however, the significance of these practices in 
spreading the disease has been minimally investigated.  
Studies from the Middle East showed barbers had low to moderate awareness that hepatitis 
can be transmitted by contaminated razors, 46% of shaves were done with reused razors, 
HBV DNA was detected in 6.6% of used razor blades and cuts from barbershops are 
associated with HBV transmission with an odds ratio of 4.74 (Ali et al., 2009) (Al-Rabeei et 
al., 2012) (Eroglu et al., 2010) (Alswaidi and O'Brien, 2010).  
As for tattooing, in a cross sectional study in Iran, tattooing was found to be an independent 
risk factor for being chronically infected with HBV (Jahangirnezhad et al., 2011).  
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3.4 Epidemiology of hepatitis B in Oman 
Oman is categorised as a country with intermediate endemicity for hepatitis B with a 
prevalence of 2-7% of the total population being infected with the virus. Following the 
geographical distribution of HBV genotypes, genotype D is expected to be the most prevalent 
genotype in Oman (Kramvis et al., 2005). In this section, a summary of what is known about 
hepatitis B in Oman is outlined. 
3.4.1 Disease surveillance system in Oman 
A Disease Surveillance System has been functioning in Oman since 1991. This system aims 
to reduce the incidence of health care associated infections, to set up an effective epidemic 
preparedness system, to achieve the highest possible levels for early detection of 
communicable diseases, and to reduce the incidence of vaccine-preventable and non-vaccine-
preventable communicable diseases. Specified infectious diseases are required to be notified 
to the system and are classified in three groups depending on the time frame in which they 
have to be notified within. Hepatitis B is classified in Group B diseases which must be 
notified within seven days of presentation. Patients presenting with symptoms of acute 
hepatitis (jaundice, malaise, anorexia with supporting laboratory findings i.e. elevated 
bilirubin or ALT) are to be screened for viral hepatitis (Bhat et al., 2005). The blood sample 
is firstly screened for hepatitis A virus. Negative cases will then be screened for HBsAg, and 
if positive, will then be tested for HDV to rule out dual infection. However, if HBsAg status 
is negative, the blood sample will be tested for HCV. Cases negative for HCV will then be 
screened for hepatitis E virus. 
3.4.2 Descriptive epidemiology of the incidence of acute hepatitis B in Oman 
The MoH in Oman reports the number of notified cases in their Annual Health Reports. Data 
derived from these reports are presented in graphs here in order to describe the incidence of 
AHB by time, person and place. This will be compared with the situation in Saudi Arabia 
where published literature was available. 
Figure 3.2 shows the incidence of acute hepatitis total (includes HAV, HBV, HCV, HEV, 
HDV and others) in comparison with AHB. It can be seen that the pattern of AHB in Oman 
was consistent from 1991 to 1996. In 1999, the incidence of HBV was a very small 
proportion of total acute hepatitis. The overall decreases in acute HBV cases were mainly 
attributed to the introduction of HBV vaccine in 1990 to the Expanded Program of 
Immunization. However, the steep decline noted in 1997 was due to the changes in the 
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confirmatory laboratory testing from latex test to ELISA test which is more specific (CDSC 
Oman, 2005). Other explanations of the decline is the vaccination of high risk groups, 
improvement of lifestyle, universal screening of blood and blood products in blood banks, 
and increased knowledge and safety in clinical practices (Abdo et al., 2012a). 
 
 
Figure 3.2 The incidence of acute hepatitis total and hepatitis B in Oman since 1991 till 2005 
Data source: CDSC quarterly reports 
Figure 3.3 shows the number of notified cases of AHB from 1995 to 2012 in Oman by age. It 
can be seen that the age groups of 1-4 years and 5-9 years accounted for most of HBV cases 
before the year 2000. This is compatible with early horizontal transmission of HBV in young 
children being the most predominant mode of HBV transmission in the Middle East (Toukan, 
1990). Symptomatic hepatitis B is rare at this young age (Shiffman, 2010) and only acute 
(mainly icteric) cases are screened for the virus surface antigen (HBsAg). Also, jaundice is 
also a symptom of haemolytic blood disorders such as haemoglobinopathies, which are 
prevalent in Omani children (Al-Riyami and Ebrahim, 2003) and which may explain the high 
detection rate at this young age. Symptomatic haemoglobinopathies was found to be 3.1 per 
1000 live births during 1989-1992 (Rajab et al., 2000).  
A decline in the incidence of hepatitis B in these two age groups started in 1997. After 2004, 
no HBV positivity was reported in these age groups and adults accounted for most of the 




































































































positivity and increasing age (p<0.001) with a mean age of 32.4± 16.2 years (Bhat et al., 
2005). In Saudi Arabia, a higher mean age of HBV infection of 37±16.2 years was reported 
from 2000 to 2007 (Memish et al., 2010). The majority (97.9%) of them were above the age 
of 15 (p<0.001). 
 
Figure 3.3 The number of acute hepatitis B from 1995 to 2012 by age 
Data source: CDSC quarterly reports 
Unfortunately, data regarding the incidence of hepatitis B by gender is not reported by the 
Communicable Diseases Control and Surveillance Department in Oman. However, a study 
from Al Dakhliya region found no significant association between HBV infection and gender 
from 2003 to 2004 (Bhat et al., 2005). Similar male to female proportion was also noted in 
another study that looked at the characteristics of hepatitis B in a sample of patients followed 
up at a tertiary referral centre in Muscat (Al-Naamani et al., 2013). On the contrary, male 
predominance for HBV positivity in Saudi Arabia was significant (p<0.001) with a relative 
risk of 1.8 in adults (Abdo et al., 2012a). 
Figure 3.4 shows the cumulative incidence of hepatitis B (per 100,000) in the regions of 
Oman from 2003-2010. It is shown that Al Wusta and Musandam are responsible for most of 
HBV cases per 100,000 people. This is possibly because these regions are more rural than the 


































Figure 3.4 The cumulative incidence of hepatitis B (per 100,000) in Oman from 2003-2010 by regions. 
Data source; CDSC and 2010 census data 
The data above underestimates the real incidence of acute hepatitis B in Oman. This is 
because symptomatic hepatitis is directly dependent on the age of infection, as discussed in 
chapter two (see 2.3.1). Jaundice develops in only 30% of acutely infected patients which 
means that the real incidence of AHB is underestimated by at least 70% by this passive 
surveillance. Moreover, differentiating between AHB and CHB with acute flare is not 
possible by screening for HBsAg alone. Anti-HBc IgM is the most specific marker for acute 
infection. However, it is not available for screening due to its high cost (Bhat et al., 2005).  
3.4.3 The prevalence of hepatitis B in specific Omani populations  
There has not been any population-based study conducted to calculate the prevalence of 
hepatitis B in Oman. However, studies investigating the prevalence of the infection in 
specific populations such as pregnant women and blood donors are available. 
Al Awaidy et al conducted a cross sectional study in 2005 to evaluate the prevalence of 
hepatitis B markers among pregnant women in Oman and two other GCC countries; United 
Arab Emirates and Qatar. The study revealed that HBsAg positivity was higher among 
Omani pregnant women (7.1%) compared to those in other GCC states (UAE 1.5% and Qatar 








































positive for HBeAg (0.5%). The study revealed that HBsAg positivity was significantly 
higher in women ≤24 years (adjusted OR 2.4, 95% CI 1.367-4.336, p= 0.0025). These 
findings indicate that the risk of vertical transmission of hepatitis B in Oman is not fully 
eradicated yet. Although HBV vaccine was introduced at the same time in these three 
countries, the prevalence remains higher in Oman which raises questions regarding the 
efficacy and coverage of the vaccine in Oman. 
Furthermore, Kaminski et al. evaluated the prevalence of HBV markers among Omani blood 
donors in the same year (Kaminski et al., 2006). They found that 20.5% of blood donors had 
been infected with HBV in the past (anti-HBc positive). They also found that HBsAg 
positivity was present in almost 3% of blood donors. The findings of these two studies by Al 
Swaidy and Kaminski are compatible with the estimated intermediate national prevalence of 
hepatitis B in Oman. 
3.4.4 Risk factors associated with hepatitis B in Oman 
No studies in Oman were specifically aimed to evaluate the risk factors associated with HBV 
transmission among Omani patients. However, some studies revealed an association between 
some medical practices and HBV positivity. When studying transplantation patients, 2.3% of 
patients from Oman and UAE developed a positive status of HBV infection after undergoing 
a commercial renal transplant in Bombay, India, from 1984-1988 (Salahudeen et al., 1990). 
Moreover, the prevalence of HBsAg is significantly higher in haemodialysis and renal 
transplant patients than in nephrology clinic patients (p= 0.05) (Aldhahry et al., 1994). These 
risks are expected to minimally contribute to HBV transmission at the present time due to 
advances in medical safety policies. When studying patients already infected with HBV, Al 
Naamani et al. reported positive family history of hepatitis B, traditional cautery (wasm), 
body piercing(s), surgery(ies) and  blood transfusion(s) in 70%, 65%, 40%, 18.2% and 4.5% 
of patients respectively (Al-Naamani et al., 2013). 
3.4.5 Control and prevention of hepatitis B in Oman 
The hepatitis B vaccine was introduced to the Expanded Program of Immunization in August 
1990 aiming to reduce the prevalence of HBV carriage to 2% in the general population. All 
new-borns well enough to be discharged from the hospital (including pre-mature and low 
weight infants), are indicated for the first HBV vaccine dose within the first 12 hours of life 
(Sultanate of Oman Ministry of Health). Active immunization using the three-dose vaccine 
plus passive immunization by administering hepatitis B immunoglobulins to neonates born to 
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HBsAg mother regardless of her HBeAg status is followed in SQUH and AFH but not in 
MoH hospitals. To increase the coverage rate of the HBV vaccination strategy, hepatitis B 
catch-up school campaigns from 2001-2004 were conducted to vaccinate school children who 
were born before August 1990.  
Other strategies were also implemented by the MoH to improve the control of the diseases in 
Oman (Sultanate of Oman Ministry of Health, 1994). These include the screening of all 
family contacts of HBsAg positive patient and vaccinating HBsAg negative children below 
the age of ten years. Moreover, there is also screening of all blood and blood products for 
HBsAg which is considered to be the gold standard screening marker for blood donors, with  
improvement in its sensitivity since it was first introduced in early 1970s (Roth, 2007).  
However, HbsAg may be undetectable in some chronic carriers with reduced levels of 
HBsAg, patients in the AHB window period and mutations in the ‘a domain’. Therefore, 
some countries introduced testing for anti-HBc alongside HBsAg testing to further reduce the 
risk of transmissible infection. In Oman, evidence of occult HBV infection was noted in 
20.5% of HBsAg negative donors (Kaminski et al., 2006) and anti-HBc testing was only 
introduced in November 2008. Also, the Moh strictly recommends the implementation of 
precautionary measures while handling blood or body fluids. All health care workers must be 
immunised against the virus. 
Screening of patients in dialysis units for HBsAg is also recommended by the MoH 
(Executive Board of the Health Ministers’ Council for GCC States, 2009). All HBsA 
negative patients and staff working in the unit are to be vaccinated against the virus. Patients 
with poor response to the vaccine (anti-HBs<10 miu/ml) should be revaccinated and retested 
annually. With respect to HBsAg positive patients, isolation of dialysis machines, areas and 





4 MAJOR RISK FACTORS FOR ACQUIRING HEPATITIS B INFECTION 
AMONG HBsAg POSITIVE PATIENTS IN OMAN 
4.1 Introduction: 
Risk factors for the spread of HBV vary between nations depending on the endemicity of the 
disease. Risk factors specific to the Omani population have been minimally evaluated. Family 
history of hepatitis B, wasm (an alternative medical practice used to treat jaundice by 
applying a hot metal implement to the skin), body piercings and surgeries were found 
common among a group of Omani patients (Al-Naamani et al., 2013). Identifying the risk 
factors associated with the transmission of HBV in Oman is essential to achieve effective 
control of the infection and to explore the groups that are at higher risk. It would also enable 
us to detect any changes/shift in the mode of the transmission. 
This chapter will describe the methods, results and discussion of a cross sectional study 
which aims to identify the prevalence of HBV transmission risk factors among Omani 
patients with active hepatitis B. 
4.2 Aims: 




Subjects were recruited from outpatient clinics. At SQUH, the hepatitis outpatient clinic is 
run weekly. Along with other hepatitis aetiologies, HBV positive patients are seen routinely 
at this clinic for consultations. During the period from 27 February 2013 till 4 July 2013, a 
total of 17 clinics were attended and the clinic was closed for two weeks.  The medical files 
of patients waiting at the clinic were checked for HBsAg positivity. Those positive for 
HBsAg were approached by me and asked if they would be interested in participating in a 
study. Patients agreeing to participate were then taken to a private room where the study was 
explained in more detail to the participants. An information sheet was given to them to read 
before signing the consent form. For participants who could not read, the information sheet 
was read and explained to them by either me or their chaperone. Not all HBsAg positive 
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patients were approached to participate, as some did not attend scheduled appointments or I 
was unable to see them. 
At AFH, patients were recruited by two different methods. The first method was face to face 
interviewing of patients attending Dr Al Naamani’s, hepatology consultant at AFH, OP clinic 
every week. Not all HBV patients followed at AFH were seen by Dr Al Naamani, but clinics 
were run on different days and I was only able to attend that one clinic. From 11 March 2013 
till 2 July 2013, a total of 13 clinics were attended (11 with Dr Al Namani and 2 with Dr 
Kamath). Unlike at SQUH, patients were referred to be seen by me by the doctors either 
before or after their consultation. 
The other method of recruiting patients from AFH was by telephone interview. The data and 
contact details of 156 hepatitis B patients were given to me. Those patients had taken part in a 
recent retrospective study that looked at the characteristics of HBV infection. The data 
included patients’ demographic characteristics, history of HBV risk factors, and laboratory 
findings. Only the demographic data and history of HBV risk factors were used. Patients 
were called to inquire about other risk factors that were not included in the previous study 
such as hepatitis B awareness and history of endoscopy, dental treatment, traditional 
phlebotomy, barber shaving and circumcision. As this study was conducted from 2009 till 
2011, patients’ date of birth was obtained to calculate their current age. The study was 
explained to the patients and verbal consent was obtained before starting the interview. 
Ethical approvals were obtained from University of Otago, SQUH and AFH Human Ethics 
Committee prior to commencing the study. 
Inclusion criteria: 
Omani patients with positive HBsAg aged 13 years and above were attending the hepatology 
outpatient clinics during the time frame mentioned above. Patients who agreed to participate 
and sign the consent form, or gave verbal consent were included in this study. As for patients 
interviewed over the phone, those with available contact numbers were included. 
Exclusion criteria: 
HBsAg negative HBV patients, non-Omani patients, patients seen twice and those with 





Data was collected using a two page questionnaire recording patients’ demographic 
characteristics such as age, gender, marital status, educational level and occupation 
(Appendix). Participants were also questioned about their immunization history and their 
frequency of exposure to identified and potential risk factors for HBV transmission prior to 
their date of diagnosis. Those risk factors include: history of hospitalization, major surgeries, 
organ transplantation, blood transfusion, endoscopy, hemodialysis, chemotherapy, dental 
visits and contact with infected people.  
The questionnaire was derived from known and suggested risk factors in the international 
literature and the questions were also discussed with the senior hepatology consultants at 
AFH and SQUH. Each interview took five to 15 minutes and patients were given the chance 
to ask any questions before and after finishing the questionnaire. 
All questionnaires were administered by the interviewer, which was always me, during the 
interview, except for one patient who requested the Arabic version of the questionnaire and 
filled it in by himself.  
4.4 Analytical methods: 
Demographic variables 
Participants were grouped in three different age groups depending on the HBV immunization 
program in Oman. The three age groups were; 13-<23 for patients born after the introduction 
of HBV vaccine to Expanded Program of Immunization in August 1990, 23-28 for patients 
born before August 1990 but who presumably had completed the catch-up school vaccine 
campaigns completed in 2004-2005, and finally >28 for patients born before that. 
Depending on marital status, patients were classified as “ever married”, which also include 
divorced and widowed, and “non-married”, which included single and engaged participants. 
Occupations were classified as non-risk occupations and high-risk occupations. High-risk 
occupations included nurses, medical doctors, medical orderlies, medical assistants, medical 
students, policemen, dentists, sex workers, blue-collar employees, barbers and beauticians 




Grouping of risk factors 
Risk factors for the transmission of HBV were grouped as nosocomial, family exposure or 
high risk behaviors. Nosocomial risk factors included history of hospitalization, major 
surgery, organ transplantation, endoscopy, blood transfusion dialysis and dental treatment. 
Family related risk factors included; family history of HBV, current living with HBV infected 
individuals (later classified as sexual or non-sexual contact), mothers’ history of HBV and 
finally, family history of liver disease. High-risk behaviours included: uunawareness about 
HBV infection, piercings, regular shaving with a barber, wasam, traditional phlebotomy, 
acupuncture, circumcision, multiple sexual partners. Participants were asked for the place 
where piercing or circumcision was done, which was then classified as clinical and non-
clinical settings.  
During the interviews, frequency of risk factors was recorded as 0, 1, ≥2. However, this was 
changed to yes or no for analytical purposes.  
Statistical analysis 
The sample size required was determined by the number of patients that could be interviewed 
during the data collection period. This was expected to be 300 patients.  In a previous study 
of CHB carriers in Iran that looked at 560 patients they found that endoscopy, major surgery 
and tattooing were independent risk factors for CHB with percentages of 54.8%, 44.5% and 
8.5% respectively (Jahangirnezhad, 2011). If the situation was assumed to be similar in 
Oman, a sample size was 300 participants would enable us to estimate the proportion tattooed 
with 95% confidence intervals of approximately ±5%, and the proportion with endoscopy or 
surgery with 95% CI of approximately ±6%. 
Epi info version 7 was used to calculate the frequency of HBV transmission risk factors in the 
total studied population. The risk factor frequency was stratified by age groups (13-<23, 23-
28, <28), sex (male and female) and educational level (pre-secondary, secondary and post-
secondary). 
A chi-square test was performed to examine the association between risk factor frequency 
and gender, age or educational level and reported when significant. A P value of < 0.05 was 




Out of 365 HBV positive patients eligible to participate in this study, only 274 were included 
in the final analysis. A total of 92 patients were excluded (figure 4.1). The number of patients 
who did not attend the outpatient clinic or who I was unable to interview was not recorded 
but I estimate it to be one to two patients per clinic (total 30-60 patients). 
 
 
Figure 4.1 Flow chart showing the process of recruiting patients  
 
The demographic features are summarised in Table 4.1. The median age for men was 35.9 
year and for women 35.1 year with 75.5% of them in the age range of 20 - 39 (Figure 4.2). 
The majority of the participants came from Al-Batinah (32.1%), Al-Dakhiliya (25.1%), 
Muscat (19.0%) and Al-Sharqiyah (16.4%) regions (table 4.1). A minority of participants 
(3.7%) worked in high risk jobs which included; 3 nurses, 2 policemen, 1 doctor, 1 medical 
student, 1 medical assistant and 1 medical orderly. 
 
Total number of HBsAg positive 
patients interviewed at SQUH 
=138
Total number of HBV patients 
to be interviewed over the 
phone =156
Total number of HBsAg positve 
patients who met the inclusion 
criteria =274
Total number of HBsAg positive 
patients interviewed at AFH 
=71  
4 excluded: 
 2 with incomplete 
questionnaires. 




 22 had already 
been interviewed 
in the clinic. 
 8 negative 
HBsAg status. 




Table 4.1 Demographic characteristics of the participants 
Variable Number Percentage 
No. of participants 274  























Al-Dhahirah 14 (5.1%) 
Al-Buraimi 1 (0.4%) 
Al-Wusta 1 (0.4%) 
Dhofar 2 (0.7%) 
Educational level   
Illiterate 15 (5.5%) 
Write and read 5 (1.8%) 
Elementary 20 (7.3%) 
Primary 21 (7.7%) 
Secondary 112 (40.9%) 
Diploma 27 (9.9%) 
Bachelor 70 (25.5%) 
Masters 3 (1.1%) 
PhD 1 (0.4%) 
Marital status   
Married 244 (89.1%) 
Not married 30 (10.9%) 
Occupation   
Non-high risk occupations 








Figure 4.2 Age distribution of participants 
Blood donation was found to be the most common way in which HBV was diagnosed in 
males (44%), while antenatal screening was the most common means of diagnosis in females 
(47%). Blood test for other reasons (e.g. after birth, after surgery, abdominal pain, multi 
transfusion screen, health check-up) was the second most common source of diagnosis in 
both genders. The least common means of diagnosis in both genders was contact screening 
(Table 4.2). 
Table 4.2 HBV means of diagnosis 
Means of diagnosis Gender 
 male female 
Antenatal screening 0(0%) 61(47%) 
Blood donation 63(44%) 10(8%) 
Blood test 50(35%) 38(29%) 
Symptomatic 9(6%) 7(5%) 
Family screening or sexual contact screening 2(1%) 2(2%) 
Pre-employment test 7(5%) 11(8%) 
Others 12(8%) 2(2%) 
 
Table 4.3 summarizes the prevalence of HBV transmission risk factors grouped as 
behavioural risk factors, perinatal and household contact or nosocomial risk factors. The 
result of each group is presented in more details in Tables 4.4, 4.5 and 4.6. 
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 It is apparent that high risk behaviours were very common in this study population with 
similar distribution in the two age groups. Almost two thirds of the participants had histories 
of perinatal and household contact transmission risks which were more common in those 
under the age of 28 years. 60.2% of the interviewees had at least a history of nosocomial 
risks. Only one participant reported no history of HBV acquisition risk factors. 
Table 4.3 Prevalence of  HBV transmission risk factors in this study group 




CI Age 13-28 yr 
(n=62) 






Lack of knowledge 




















Family related risk 
factors 
 




165(60.2%) 67.6-52.8 35(56.5%) 48.1-64.9 130(61.3%) 52.9-69.7 
No risks 1(0.4%) -5.3-7.3 0(0%)  1(0.5%) -6-7.5 
 
Table 4.4 shows the frequency of nosocomial risk in this study population which appear to be 
low. The majority of participants had no history of surgery (70.4%), hospitalization (71.9%), 
blood transfusion (91.2%) and endoscopy (93.4%). Only one patient had a history of dialysis 
and none of the participants had a history of organ transplantation. With further statistical 
analysis, significant difference in the frequency of endoscopy between age groups was noted, 
but the number of participants in the 13-18 years was smaller than that in the two remaining 
age groups. The Chi-square test did not show any significant difference in the frequency of 
other nosocomial risk factors between sex, age and educational level. 
When trying to assess the effect of perinatal, early horizontal and spousal transmission of 
HBV among participants (Table 4.5), more than half of the participants had a positive family 
history of HBV infection (father, siblings or cousins). This was significantly different 
between sexes, P <0.02 and educational level P =0.0019. Significant difference was also 
found between the three age groups (<23, 24-28, >28) in mothers’ HBV positivity (33.3%, 
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14.3%, 6.6% respectively, P <0.05). Contact with HBV infected persons appeared to be 
statistically significantly difference in different educational levels P <0.05. 
Table 4.6 shows the prevalence of high risk behaviours in the participants. A minority of 
participants indicated histories of tattoos (0.4%), acupuncture (1.5%), traditional phlebotomy 
(5.1%), extra-marital sexual contact (8.8%) and circumcision in non-clinical settings (13.5%). 
The frequency of circumcision in non-clinical settings decreased significantly by the increase 
in educational levels (P= 0.04). Unawareness about HBV infection (82.1%), piercing in non-
clinical settings (46.7%), regular shaving with a barber (46.7%), wasam (49.6%) were more 
common in this studied group. There was a significant association of hepatitis B and age 
groups, and educational levels (P <0.05 and P <0.001 respectively). The relation between 





Table 4.4  Frequency of nosocomial risk factors by gender, age and educational level. 
 Total gender Age Educational level 
Nosocomial risk 
factors 
















81(29.6%) 37(25.9%) 44(33.6%) 4(66.7%) 16(28.6%) 61(28.8%) 21(34.4%) 36(32.1%) 24(23.8%) 
Hospitalization 
 
77(28.1%) 42(29.4%) 35(26.7%) 3(50.0%) 13(23.2%) 61(28.8%) 18(29.5%) 25(22.3%) 34(33.7%) 
Blood transfusion 24(8.8%) 13(9.1%) 11(8.4%) 0(0%) 5(9.0%) 19(9.0%) 7(11.5%) 12(10.7%) 5(5.0%) 
          
Endoscopy* 
 
18(6.6%) 11(7.7%) 7(5.3%) 2(33.3%) 2(3.6%) 14(6.6%) 8(13.1%) 6(5.4%) 4(4.0%) 
 





Table 4.5 Frequency of family related risk factors by gender, age and educational level 
 Total gender Age Educational level 














Maternal history of 
HBV   
    
* 
     
yes 24(8.8%) 8(5.6%) 16(12.2%) 2(33.3%) 8(14.3%) 14(6.6%) 2(3.3%) 13(11.6%) 9(8.9%) 
No 100(36.5%) 52(36.4%) 48(36.6%) 3(50.0%) 18(32.1%) 79(37.3%) 22(36.1%) 39(34.8%) 39(38.6%) 
Unknown 150(54.7%) 83(58.0%) 67(51.2%) 1(16.7%) 30(53.6%) 119(56.1%) 37(60.7%) 60(53.6%) 53(52.5%) 
Family history of 
HBV  
 **     **   
Yes 150(54.7%) 67(46.8%) 83(63.4%) 4(66.6%) 36(64.3%) 101(51.9%) 19(31.1%) 65(58.1%) 66(65.3%) 
No 61(22.3%) 35(24.5%) 26(19.8%) 1(16.7%) 8(14.3%) 52(24.5%) 21(34.4%) 24(21.4%) 16(15.8%) 
Unknown 63(23.0%) 41(28.7%) 22(16.8%) 1(16.7%) 12(21.4%) 50(23.6%) 21(34.4%) 23(20.5%) 19(18.8%) 
Contact with HBV 
infected person   
 ***     ***   
Sexual contact 31(11.3%) 11(7.7%) 20(15.3%) 1(16.7%) 8(14.3%) 22(10.4%) 4(6.6%) 16(14.3%) 11(10.9%) 
Non-sexual contact 117(42.7%) 54(37.8%) 63(48.1%) 2(33.3%) 27(48.2%) 88(41.5%) 16(26.2%) 51(45.5%) 50(49.5%) 
No contact 95(34.7%) 58(40.6%) 37(28.2%) 2(33.3%) 12(21.4%) 81(38.2%) 28(45.9%) 35(31.3%) 32(31.7%) 
Unknown 31(14.0%) 20(16.1%) 11(8.4%) 1(16.7%) 9(16.1%) 21(9.9%) 13(21.3%) 10(8.9%) 8(7.9%) 
Family history of 
liver disease 





















Unknown 48(17.5%) 28(19.6%) 20(15.3%) 1(16.7%) 12(21.4%) 35(16.5%) 16(26.2%) 17(15.2%) 15(14.9%) 
* significant difference in mother’s history of HBV infection by age, x²= 9.5164, d.f. = 4, P <0.05) 
** significant difference in  family history of hepatitis B by gender, x²= 9.0944, d.f. = 3, P <0.02 and educational level x²= 20.9362, d.f. = 6, P =0.0019 
*** living with HBV infected persons significantly differed between the three educational level groups (x²= 19.1856, d.f. = 6, P <0.05) 
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Table 4.6 Frequency of high risk behaviours by gender, age and educational level 
 Total gender Age Educational level 
High risk 
behaviours 








Lack of knowledge 




















clinical settings   
128(46.7%) 15(10.5%) 113(86.3%) 3(50.0%) 21(37.5%) 104(49.1%) 33(54.1%) 48(42.9%) 47(46.5%) 
Regular shaving 
with a barber   
128(46.7%) 128(88.8%) - 2(33.3%) 22(39.3%) 104(49.1%) 25(40.9%) 54(48.2%) 49(48.5%) 
Cautery(Wasam)**   132(49.6%) 75(52.4%) 61(46.6%) 1(16.7%) 21(37.5%) 114(53.8%) 39(63.9%) 55(49.1%) 42(41.6%) 
Traditional 
phlebotomy 
14(5.1%) 6(4.2%) 8(6.1%) 1(16.7%) 3(5.4%) 10(4.7%) 5(8.2%) 5(4.5%) 4(4.0%) 
Acupuncture 4(1.5%) 1(0.7%) 3(1.7%) 0(0%) 0(0%) 4(1.9%) 2(3.3%) 0(0%) 2(1.9%) 
Circumcision in 
non-clinical 





















24(8.8%) 24(16.8%) 0(0%) 1(16.7%) 2(3.6%) 21(9.9%) 6(9.8%) 11(9.8%) 7(6.9%) 
IDU - - - - - - - - - 
*Significant difference in hepatitis B awareness by age and educational level (x²= 6.8664, d.f. = 2, P <0.05) and (x²= 22.8042, d.f. = 2, P <0.001) respectively. 
** Significant difference in wasam by gender, age and educational level (x²= 7.0807, d.f. = 2, P <0.02), (x²= 10.5833, d.f. = 4, P <0.05), (x²= 10.5394, d.f. = 4, P =0.03) respectively. 




Research to determine the major risk factors for transmitting HBV in Oman has been lacking. 
This survey was conducted to determine the prevalence of major risk factors for acquiring 
hepatitis B infection among Omani patients positive for hepatitis B surface antigen. As there 
has not been a control group in this study, it is not possible to assess the causative role of risk 
factors for HBV acquisition in Oman. However, the results of this study will provide further 
understanding of the epidemiology of hepatitis B in Oman and it will aid in identifying the 
people who are at higher risk of acquiring HBV.  
There were several key findings from this survey. These include; similar numbers of male 
and female patients with the majority aged 20 – 39 years. The geographic distribution of the 
participants surveyed reflects that of the general population. Antenatal screening is found to 
be the most common method by which the female participants were diagnosed with hepatitis 
B. This is in contrast to males in whom blood donation was reported to be the most common 
method of diagnosis. As for HBV transmission risk factors, nosocomial risk factors were less 
common in this group of patients than intrafamillial and behavioural risks. Knowledge about 
HBV infection was scarce among our participants. 
There are some strengths and weaknesses in this study. One of the strengths is the use of a 
standard questionnaire containing closed questions throughout the study. The same 
interviewer filled all the questionnaires during a direct interview with the participants for 
consistency. This way, any misinterpretations of questions by patients were corrected at the 
time of the interview thus minimizing any false reporting. Moreover, any potential 
heterogeneity in reporting that may have arisen from using two interviewing methods (face to 
face vs. telephone) would be expected to be minimised. Another strength is that both 
hospitals screen pregnant women for HBsAg, this would give a more accurate representation 
of hepatitis B distribution between genders. 
The limitations of this study might arise from referral bias and recall error. Referral bias from 
recruiting patients from tertiary referral hospitals, SQUH and AFH, could play a role in this 
study. Patients under the age of 13 years are not seen at the outpatient clinics where patients 
were recruited for this study. This would limit our investigations regarding vertical 
transmission of HBV and would make the findings of this study only applicable to adults in 
Oman. In addition, as both hospitals are located in Muscat Governorate, patients from regions 
outside Muscat are underrepresented. This was noted for Dhofari patients. Only 0.7% of our 
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participants came from Dhofar Governorate, while CDSC reports show that Dhofar 
governorate accounted for almost a quarter of the cumulative incidence of AHB from 1991 to 
2010 (Sultanate of Oman Ministry of Health, 2012). Risk factors for HBV transmission might 
differ in Dhofari patients compared to the general population. 
In any study in which data is collected during an interview with the patients, recall error is 
expected to occur especially in patients with chronic infection, patients diagnosed with the 
disease a long time ago and older patients who have a long history. Patients may report that 
an exposure (risk factor) preceded the outcome (hepatitis B) even if it actually occurred after, 
hence, overestimating the role of these risk factors in this group of patients. Using the date of 
diagnosis as the reference date helped to minimise this recall error. In addition, risk factors 
such as sexual activity or intravenous drug use are difficult to investigate and may be 
underestimated due to the sensitivity of these issues culturally and religiously in Oman.  
The male to female ratio was almost equal to one. This finding is consistent with other 
studies conducted in Oman (Al-Naamani et al., 2013) and Iran (Alavian et al., 2012) (Merat 
et al., 2009). On the other hand, men account for most of HBV cases in most parts of the 
world (Abdo et al., 2012a) (Memish et al., 2010) (Robinson et al., 2005) (Custer et al., 2004) 
(Alswaidi and O'Brien, 2010) (Toukan and Group, 1990) (Custer et al., 2004) (Centers for 
Disease and Prevention, 2004) (World Health Organization, 2002 #25). It may be that Oman 
has a different epidemiology of hepatitis B or this might be a result of referral bias.  Patients 
were diagnosed from antenatal screening for females and blood donation for males in similar 
proportions (47% vs. 44%).  
Almost three quarters of the participants lie in the 20 – 39 age group. Generally, this would 
contribute indirectly to economic burden associated with job loss, reduced work productivity 
and premature death (Yang et al., 2001). Specifically, most of the female patients were of 
child-bearing age which maintains the risk of mother to child transmission of hepatitis B. 
Iatrogenic risk factors seemed to be the least frequent among our participants. Almost one 
third of participants have a history of surgery, which was the most prevalent nosocomial risk 
factor. A case-control study from Iran, which has a similar hepatitis B prevalence to Oman, 
found that a history of surgery is an independent risk factor for CHB carriage 
(Jahangirnezhad, 2011).  On the contrary, studies conducted in Arab and African countries 
showed insignificant role of surgical interventions in transmitting HBV (Gasim et al., 2013). 
Therefore, it is difficult to assess the real impact of surgical interventions in transmitting 
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hepatitis B. None of the participants reported any history of organ transplantation or 
haemodialysis. This may be because the majority of participants were of young age, whereas 
such treatments are usually associated with end stage disease occurring later in life. It may 
also reflect the sample size and particular clinic populations.  
Intra-familial transmission of hepatitis B can be through vertical or horizontal mode by either 
sexual or non-sexual contact. The latter is thought to be the predominant mode of hepatitis B 
transmission in the Middle East. (Toukan and Group, 1990). In the current sample, only 8.8% 
of participants reported positive mother status for HBV which was significantly associated 
with the age of participants (p<0.05), while more than half of the participants reported 
familial contact with HBV positive persons (11.3% sexual contact vs. 42.7% non-sexual 
contact).  The majority of the participants who reported sexual contact also have siblings with 
HBV. This suggests the possibility of the infection occurring earlier in life. HBV is a highly 
infective virus and HBeAg is most prevalent in children, a fact which is associated with the 
high infectivity rate (Toukan and Group, 1990). Shared use of contaminated materials such as 
razors, tooth brushes, towels, eating utensils may account for early horizontal transmission of 
HBV among family members (Urganci et al., 2013) (Alswaidi and O'Brien, 2010) (Toukan 
and Group, 1990) while the availability of sanitisation tools within the household are reported 
to be protective against transmission (Ben-Alaya-Bouafif et al., 2010). Contact with an HBV 
positive person was found to be significantly associated with the participants’ educational 
level (p< 0.05), which reflects the socio-economic status of the individual. Although lower 
educational level and lower income are identified risk factors for HBsAg positivity in both 
high and intermediate endemicity regions (Zhang et al., 2013) (Merat et al., 2009), we found 
higher contact with HBV positive patients reported by higher education groups. This might 
be because highly educated persons are more likely to know about the health status of their 
family members. 
From this survey, high-risk behaviours were noted to be common in this group of patients. 
The majority of females had piercing in non-clinical settings and a similar proportion of 
males shaved regularly with barbers. Determining the role of these practices in transmitting 
HBV is difficult as it is poorly researched within the region. Although body piercing has been 
identified as a potential risk factor for HBV infection (Zhang et al., 2013) (Zhang et al., 
2008), a recent study in the Netherlands found that body piercings did not increase the risk of 
HBV infection for the Dutch population (Urbanus et al., 2011). While this may be true for the 
Netherlands where HBV endemicity is low and hygiene guidelines have been introduced in 
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piercing shops, in Oman HBV is more endemic and most of our participants had their 
piercings at home. Moreover, piercings for females are usually done at a young age in Oman 
where the risk of chronic carriage is higher (Goldstein et al., 2005). 
 With respect to barber practices, studies from the Middle East showed barbers had low to 
moderate awareness that hepatitis can be transmitted by contaminated razors, and 46% of 
shaves were done with reused razors (Ali et al., 2009) (Al-Rabeei et al., 2012). HBV DNA 
was detected in 6.6% of used razor blades and cuts from barbershops are associated with 
HBV transmission with an odd ratio of 4.74 (Eroglu et al., 2010) (Alswaidi and O'Brien, 
2010). Despite the effort of the Omani government to ensure the safety of these practices by 
requiring the availability of sanitization areas and tools in all barber shops with regular 
inspection, their contribution to HBV transmission cannot be ruled out entirely. 
None of the participants in our study reported a history of intravenous drug use and only 
16.8% reported multiple sexual partners. Such risk factors are the most common modes of 
HBV transmission in lower endemicity regions in Western societies. In the USA, sexual 
contact (heterosexual or homosexual) and IDU account for 40.9% and 18.2% of AHB 
respectively (Goldstein et al., 2002). In China, on the other hand, where HBV is of high 
endemicity, no association between AHB and sexual contact or IDU was found in univariate 
and multivariate regression analyses (Zhang et al., 2008). The reason for this may be the 
similar attitude of Chinese and Omani people towards these behaviours. Studies in the Middle 
East reported that HBV prevalence among IDU ranges between 6% to 44.3% (Ali et al., 
2009) (Jahangirnezhad, 2011). 
Antenatal screening seems to be one of the most effective detection strategies for women in 
our sample and almost half of the female participants were discovered to be HBsAg positive 
during pregnancy. Despite the evidence of higher prevalence of HBV infection among Omani 
pregnant women (7.1%) compared to those in other GCC states (Saudi Arabia 1.6%, UAE 
1.5% and Qatar 1%) (Al Awaidy et al., 2006) (Gasim et al., 2013), antenatal screening for 
HBsAg is not available at MoH institutes. With the introduction of neonatal vaccination in 
1990, it would take around 20-40 years for the vaccine alone to eliminate vertical 
transmission of HBV in Oman. The Royal Australian and New Zealand College of Obstetrics 
and Gynaecology recommends routine screening of all pregnant women for HBsAg, and the 
administration of active and passive vaccination for infants born to HBsAg positive mothers 
(Troung and Walker, 2013). These measures are associated with 90-100% effectiveness in 
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preventing the transmission of the virus in neonates born to mothers with HBV infection (Hu 
et al., 2012) and should consider in Oman. However, in mothers positive for HBeAg with 
high viral load, post prophylaxis failure is possible and treatment within the third trimester 
should be considered. Anti-viral therapy with lamivudine for pregnant women with abnormal 
ALT levels, positive for HBsAg and HBeAg, have HBV DNA ≥1.0×107 copies/mL, during 
the gestation period between 24-32 weeks, decreases intrauterine HBV infection along with 
the vaccine and immunoprophylaxis for the new-born babies (Yu et al., 2012). 
Despite the evidence of common contact with HBV positive family members among the 
participants, only 1.5% were diagnosed from contact screening. This suggests that contact 
screening is not being widely applied. Greater focus on contact screening could aid in the 
control of HBV infection in Oman by identifying non-immune contacts and vaccinating 
them. Furthermore, it could act as a secondary prevention measure by identifying those with 
chronic infection, providing them with the appropriate treatment or follow up and hence, 
reduce the long term complications (cirrhosis or HCC) and mortality associated with chronic 
infection. 
The majority of our participants had no knowledge about HBV infection prior to their 
diagnosis. Educating individuals about hepatitis B risk factors could help to reduce the risk of 
spreading the virus. It has been shown that improving awareness regarding risk factors of 
HBV transmission has led to a decrease in HBV prevalence in Iran (Alavian et al., 2007).  
In conclusion, this study indicated that risk factors for HBV infection in Oman include direct 
contact of infected individuals within a family and exposure to high-risk behaviours such as 
piercing and barber shaving. While further analytical epidemiological studies are needed to 
assess the proportion of hepatitis B attributable to different risk factors, implementing 
antenatal screening for pregnant women would reduce the vertical transmission of HBV, and 
improving contact screening would reduce horizontal transmission of the virus and reduce 
morbidity and mortality associated with the virus. Future work is required to confirm the 
association with behavioural risk factors, mainly piercing and shaving at barber shops, and 




5 THE CONTRIBUTION OF HEPATITIS B TO LIVER CIRRHOSIS IN 
OMAN. 
5.1 Introduction: 
Chronic infection with HBV occurs mainly in patients acquiring the infection at young age 
either vertically or during early childhood. Cirrhosis of the liver and primary liver cancer are 
associated with the long exposure to HBV. 
Despite the strong association of HBV with so many cases of liver cirrhosis and HCC, there 
is no available literature looking at the role of HBV in relation to liver cirrhosis in Oman. 
Such an estimation would contribute to understanding of the burden of this infection in 
Oman. Further understanding of the hepatitis B outcomes will encourage public health 
measures to reduce the burden of long term consequences of CHB. 
The study outlined in this chapter aims to estimate the contribution of HBV infection to 
cirrhosis in Oman. 
5.2 Methods: 
Identifying patients: 
The study was conducted in two tertiary hospitals in Oman which are; the Sultan Qaboos 
University hospital (SQUH) and the Armed Forces Hospital (AFH). Cirrhotic patients were 
identified differently in the two hospitals. From SQUH, a list of patients diagnosed with 
either “Other or Unspecified Cirrhosis of Liver”, “Fibrosis and Cirrhosis of Liver”, 
“Alcoholic Cirrhosis of Liver” was provided by the Hospital Information System. The list 
contained the patients’ names, gender, date of birth and medical record number. Duplicates 
were removed and data of interest was collected from the patients’ computerized medical 
records. 
At AFH, cases were identified manually by going through the Admission and Discharge 
books from all the wards admitting medical cases. These wards include the green ward (male 
patients), the red ward (female patients) and the gold ward 1 (VIP cases). These books were 
dated from December 2006 till April 2012 from green ward and from January 2006 till July 
2012 from red ward. The Admission and Discharge book for the year of 2007 was not found 
from red ward. Gold ward 1 is a new ward and the admission and discharge book dated from 
March 2012 till April 2013. From those books, patient ID was collected for any cases 
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admitted for any gastrointestinal reason (e.g. abdominal pain, hematemesis, OGD, ascetic tap, 
upper GI bleed, hepatic encephalopathy, ascites, HCC, hepatitis, cirrhosis, alcohol 
withdrawal). The electronic medical records of those patients were checked through the 
Hospital Information System for the specific diagnosis of liver cirrhosis. 
Inclusion criteria: 
All cirrhotic patients that could be identified with computerized records from 2006-2013 
from SQUH and AFH were included. 
Exclusion criteria: 
Patients where a specific diagnosis of cirrhosis was not made, duplicated cases, those with 
incomplete computerized medical records (no radiology or biopsy data to confirm the 
diagnosis), non-cirrhotic portal hypertension (e.g. schistosomiasis, PV thrombosis) and non-
cirrhotic cases were excluded from this study.  
Data collected: 
The most recent electronic data of each patient was collected. The data collected included 
demographic data (age and gender). Moreover, data regarding abdominal radiology 
(Ultrasound, CT scan and/or MRI), OGD, liver biopsy, biochemical data (ALT, AST, 
bilirubin, albumin), and hematological data (INR or PT and platelet count) were also 
collected to confirm the diagnosis of cirrhosis. HBV and HCV viral markers were collected 
to assess the contribution of these viral infections to cirrhosis.  These markers were; HBsAg, 
ant-HBs, HBcAg, anti-HBc, HBeAg, anti-HBe, HBV DNA, HCV antibody, HCV RNA.  
Other data representing alpha 1 antitrypsin levels, serum copper levels, ferritin levels, 
autoimmune profile, antinuclear antibody and patients’ medical history (drug history, 
diabetes mellitus, family history of liver disease, Nonalcoholic Steatohepatitis (NASH)) and 
social history (smoking and alcohol consumption) were also collected to assess other 
etiologies of cirrhosis. 
Analytical methods: 
Confirming the diagnosis of cirrhosis: 
The histological findings of cirrhosis on biopsy is the gold standard for diagnosis (Chen et al., 
2007). However, this procedure is invasive and only 9% of the studied sample had undergone 
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biopsy. Radiological tests, on the other hand, were more common in this studied cohort. 
Radiological findings (US, CT and MRI) are not very sensitive in detecting cirrhosis; 
however, they are highly specific when the cause is known (74.1% and 84% respectively) 
(Lin et al., 1993) (Schuppan and Afdhal). Therefore, the use of radiological findings in the 
diagnosis of cirrhosis in this study is objective. 
Patients were classified into three different groups depending on the degree of certainty of the 
diagnosis. The three groups are definite cirrhosis, probable cirrhosis and possible cirrhosis. 
The diagnosis was based on histological, radiological (ultrasonography (US), Computed 
Tomography (CT) scan or Magnetic Resonance Imaging (MRI)) and laboratory tests 
(biochemical and haematological). Table 5.1 describes the criteria used in classifying the 
patients to each category. 
Table 5.1 Categories depending on the accuracy of cirrhosis diagnosis 
Category Basis of diagnosis 
Definite cirrhosis  Either presence of histological features of cirrhosis which 
include: bridging fibrous septa, parenchymal nodules and 
disruption of the liver architecture. (Kumar and Robbins, c2007) 
 And/ or irregular or undulated liver surface with heterogeneous or 
coarse echotexture on radiological images. Positive extrahepatic 
features such as enlarged spleen, collateral vessels, ascites and 
dilated PV.(Schuppan and Afdhal) 
 With/ without biochemical tests showing raised aminotransferases 
(with AST>ALT usually), raised bilirubin, decreased albumin. 
Haematological tests showing decreased platelet count and 
increased INR or PT. (Braunwald and Eugene, c2001.) 
Probable cirrhosis  Either irregular or undulated liver surface or heterogeneous 
or coarse echotexture on radiological images. With or without 
extrahepatic features such as enlarged spleen, collateral vessels, 
and ascites and dilated PV. 
 With/ without biochemical tests showing raised bilirubin and 
decreased albumin. Haematological tests showing decreased 
platelet count or increased INR or PT 
Possible cirrhosis  Biochemical tests show raised bilirubin, decreased albumin. 
Haematological tests showing decreased platelet count or 
increased INR or PT but no histological or radiological tests to 




Aetiology of cirrhosis: 
The etiology of cirrhosis was based on the specified diagnosis reported in the patients’ record 
with the aid of laboratory findings. aeitologies were classified as HCV, HBV, Alcoholic, 
cryptogenic, HBV and HCV co-infection, auto-immune, Budd-Chiari, NASH and not-
otherwise specified.  Etiologies that were uncommon in this studied population were 
classified as others. These included cardiac cirrhosis, primary biliary cirrhosis, primary 
sclerosing cholangitis, secondary sclerosing cholangitis, biliary atresia, amiodarone induced 
cirrhosis, Fanconi syndrome and Wilson’s disease. 
There were 16 patients diagnosed as Alcohol and HCV related cirrhosis and four patients 
diagnosed as Alcohol and HBV related cirrhosis. However, those patients were added to the 
HCV or HBV categories. This is because alcohol consumption is measured subjectively by 
the doctor in Oman as no specific unit is used. 
Interpretation of virological markers: 
Patients with hepatic viral aetiologies were grouped depending on the status of their viral 
markers. Positive anti-HBc indicates current or previous infection with HBV. Positive 
HBsAg indicates current infection with HBV. On the other hand, patients positive for anti-
HBc but negative for HBsAg are considered to have had past infection. Positive HCV anti-
bodies (HCV AB) status and positive anti-HBc indicate co-infection of HBV and HCV. Our 
definition of was based on the positivity of anti-HBc (rather than HBsAg) because HBsAg 
expression is usually decreased in HCV patients (Lok and McMahon, 2007) (Shih et al., 
1993) (Uchida et al., 1997). Patients with positive HCV AB alone were grouped in the HCV 
mono-infection group. 
Immunity against HBV is determined by the presence of anti-HBs. Cirrhotic patients were 
classified as either immune, non-immune or with unknown immunity status. Immune patients 
are those with positive anti- HBs, and depending on their anti- HBc status, they were further 
classified as immune due to previous infection (anti-HBc positive), immune by vaccine (anti-
HBc negative) and immune due to unknown reason (anti-HBc unavailable). Non-immune 
patients are those with negative anti- HBs status. Unknown immunity status is for patients 
where the anti-HBs status is not available. This calculation excluded patients who were 




Data was originally collected on Microsoft Excel 2010. However, all statistical analysis was 
done using Epi info version 7. This included calculating the frequencies of cirrhosis etiology, 




Out of 469 patients identified with cirrhosis from both hospitals, 419 met the criteria and 
were included in the final analysis. When categorised depending on diagnosis accuracy, 
70.9%, 10.3%, 18.8% of the study population had definite, probable or suspected cirrhosis 
respectively (figure 5.1). 
 
 
Figure 5.1 Flow chart showing the results of patients selection process 
The demographic characteristics are shown in table 5.2. Two thirds of cirrhotic patients were 
males. The youngest patient was 5 years old and the oldest was 95.The median age of the 
study sample was 59 years. The majority (97.1%) of cirrhotic patients were Omanis. Almost 
half of the group was also diabetic and more than a fifth had indicated consumption of 
alcoholic beverages. It is worth noting that there was a significant amount of missing data for 
this study population. For example, 89% of family history for liver disease was missing.  
Total number of 
crirrhosis diagnosed 
patients from SQUH 
(n= 301)  
Total number of 
cirrhosis diagnosed 
patients from AFH 
(n=168)
Total number of 
patients who met 






Possible cirrhosis (n= 
79, 18.8%)
39 excluded: 
 5 duplicate cases. 
 11 with incomplete 
medical record. 
 10 non-cirrhotic 
fibrosis. 
 13 Non-cirrhotic. 
11excluded: 
 1 duplicate case. 
 6 with incomplete 
medical record. 
 2 non cirrhotic 
fibrosis. 




Table 5.2 Patients' demographics and clinical history 
Variables Number Percentage 
General demographic profile   
No. of patients 419  



















Patients’ history   
Diabetes mellitus   
Yes  200 (47.7%) 
No  59 (14.1%) 
Not available  160 (38.2%) 
Family history of liver disease   
Yes  15 (3.6%) 
No  31 (7.4%) 
Not available  373 (89%) 
Alcohol consumption   
Yes  93 (22.2%) 
No  86 (20.5%) 
Not available  240 (57.3%) 
Smoking   
Yes  58 (13.8%) 
No  84 (20%) 





Figure 5.2 Age distribution of cirrhotic cases 
The aetiologies of cirrhosis according to diagnosis in medical records are summarised in 
Table 5.3. It shows that HBV infection accounted for 24% of patients with cirrhosis in this 
sample. When stratified by gender, HBV related cirrhosis was more common in males than 
females (29% vs. 13% respectively, p<0.01), while HCV related cirrhosis was more common 
in females than males (43% vs. 24% respectively, p<0.01). Only 2% of the studied 
population had co-infection with HCV and HBV, and 1% had HBV and alcohol related 
cirrhosis.  
Table 5.3 Aetiology of cirrhosis stratified by gender (diagnosis per patients’ medical records). 
Aetiology of cirrhosis Entire cohort (n=419) Male (n=283) Female (n= 136) 
No. (%) No. (%) No. (%) 
HCV related cirrhosis 128 (31%) 69 (24%) 59 (43%) 
HBV related cirrhosis 99 (24%) 81 (29%) 18 (13%) 
Alcohol related cirrhosis 49 (12%) 46 (16%) 3 (2%) 
Cryptogenic cirrhosis 44 (11%) 22 (8%) 22 (16%) 
HBV and HCV co-infection 7 (2%) 6 (2%) 1 (1%) 
AIH related cirrhosis 7 (2%) 2 (1%) 5 (4%) 
NASH 3 (1%) 3 (1%) - 
Budd-Chiari 3 (1%) 3 (1%) - 
Others* 10 (2%) 7 (2%) 3 (2%) 
Not otherwise specified 69 (16%) 44 (16%) 25 (18%) 
*Others included the uncommon etiologies of liver cirrhosis in this study cohort. These were: two cardiac cirrhosis, two primary biliary 
cirrhosis, one primary sclerosing cholangitis, one secondary sclerosing cholangitis, one biliary atresia, one amiodarone induced cirrhosis, 
one Fanconi syndrome and one Wilson’s disease. 
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Table 5.4 shows the distribution of hepatic virological markers in this population of cirrhotic 
patients. More than half had evidence of previous or current infection with HBV. Current 
infection with HBV was slightly more common than HCV mono-infection (19.8% vs. 
17.9%). Serological data showed higher rates of HBV and HCV co- infection than identified 
from patients’ notes (table 5.3). In the HBV positive group (anti-HBc +), 34% achieved 
HBeAg seroconversion and only 3.3% remain positive for HBeAg. There were 7 patients 
with occult HBV infection i.e. patients were positive for HBV DNA but negative for HBsAg 
(data not presented). 
Table 5.4 HBV and HCV status of the study cohort 
Definition Number (%) Serologic findings 
Current or previous HBV 
infection* 
 
215 (51.3%) Positive anti-HBc 
Current infection with HBV 
 
83 (19.8%) Positive HBsAg 
Previous HBV infection 
(with or without immunity 
development) 
 
77 (18.4%) Positive anit-HBc with negative HBsAg and/or anti-HCV 
(with or without positive anti-HBs) 
 
Concurrent infection with 
HBV and HCV  
 
53 (12.6%) Positive anti- HBc and HCV AB 
Current mono-infection with 
HCV 
75 (17.9%) Positive HCV AB 
*Note that there are two extra patients in this group which is attributed to the unknown virological status in some patients. 
Table 5.5 summarises the most recent laboratory data of the 419 cirrhotic patients by 
virological status. Cirrhotic patients found positive for HBsAg were the youngest of the 
groups. The male to female ratio was highest in patients currently infected with HBV (4.2) 
and lowest in patients currently infected with HCV (1.3). 
In general aminotransferases were elevated in all the groups, with AST being higher than 
ALT. In addition, elevated bilirubin and decreased albumin was noticed in all groups. 
Haematological tests show decreased platelet count in all groups with it being lowest in 
HBsAg + infected group (100 ×109/L). INR and PT were almost equally elevated in all 
groups.   
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HBV positive patients Co-infection 










Demography      




















Biochemical tests (median 
(range)) 
     
AST (IU/mL) 76(10-14335) 76(19-7582) 70(10-1800) 75(17-14335) 73(15-2152) 
ALT(IU/mL) 41(0-4180) 39(12-4180) 45(0-610) 45(10-3733) 38(9-634) 
Albumin 26(10-78) 24(12-44) 25(10-45) 25(10-49) 27(13-78) 
Bilirubin 
 
48.4(2-753) 39(6-659) 51.4(4.9-564) 46(3-416) 62(3.9-753) 
Haematological tests 
(median (range)) 
     
Platelets count 
(×109/L) 
105(13-513) 100(15-331) 107(30-513) 113(21-489) 109(14-462) 
INR (secs) 1.5(0.9-46) 1.5(0.9-7.5) 1.5(1-4.1) 1.6(1-19) 1.4(0.9-9.4) 
PT (secs) 18(10.2-100) 19.4(13.6-40.9) 19(10.2-100) 16.7(11-53.9) 18(11.8-36) 
 
Figure 5.3 shows that 36% of patients were immune (positive anti-HBs) against HBV with 
the majority (27%) being immune due to previous infection (anti-HBs +/anti-HBc +), 5% 
immune by vaccination (anti-HBs +/anti-HBc -) and 4% immune by unknown method (anti-
HBs +/anti-HBc unknown). 34% of the studied cohort are un-immune (anti-HBs -), and 30% 









This was a cross sectional study conducted in order to estimate the contribution of hepatitis B 
to liver cirrhosis in Oman. The study revealed that the median age of cirrhotic patients was 59 
years and males accounted for two thirds of the total studied population. Most patients were 
of Omani ethnicity. Evidence of previous or current HBV infection was present in more than 
half of cirrhotic patients in Oman. This was determined by the presence of anti-HBc. HBV 
infection was more common among male cirrhotic patients compared to females whose most 
common aetiology was HCV. 
There are multiple strengths and weaknesses to this study.  Starting with the strengths, the 
study sample is relatively large. Patients were selected carefully using well-defined exclusion 
and inclusion criteria and the definition of cirrhosis was based on objective criteria. In 
addition, as 97.1% of patients were Omani, this eliminated the effect of geographical factors 
that might alter the progress of HBV infection to cirrhosis. One of these factors is HBV 
genotype. HBV genotypes have different geographical distribution as well as different 
pathogenicity in causing further hepatic disease (Kramvis et al., 2005).  
Alcohol is a major co-factor for the development of cirrhosis. Due to the retrospective nature 
of data collection for this Omani study, a specific measurement of alcohol consumption was 
unavailable for this group of patients therefore; it was difficult to assess the synergetic effect 
of alcohol and HBV in the aetiology of cirrhosis. When combined with HBV infection, the 
natural course of the disease is affected negatively. The risk of cirrhosis increases by more 
than six times in HBsAg positive patients with history of high alcohol (Ikeda et al., 1998). In 
addition, the presence of anti-HBc alone with negative HBsAg status in patients with 
alcoholic cirrhosis was significantly associated with a more severe clinical profile (Zhang, 
2013). Moreover, information regarding diabetes and family history of liver disease was 
incomplete and mostly missing. These are also thought to affect the prognosis of hepatitis B 
with regard to cirrhosis (see 2.3.5). 
This study was also limited by the unknown status of HBV virology markers for some 
participants. For instance, HBsAg status was unknown for 9.79% of patients. This might 
underestimate the role of HBV infection in inducing cirrhosis among this studied cohort. 
Moreover, even though it was expected that the number of male patients would outweigh that 
of female patients, this number will be overestimated due to the unavailability of the 
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admission and discharge book from the red (females) ward for the year of 2007. These books 
were used to identify cirrhotic patients from the Armed Forces Hospital. 
The male to female ratio in our study was found to be higher than one in all groups with viral 
hepatitis; however, the ratio was highest in patients currently infected with HBV (4.2), and 
lowest in patients with HCV infection (1.3). It has been suggested that females are more 
likely to clear HBV and develop antibodies against it compared to males, although the 
mechanism is unknown (Al-Faleh et al., 1992). Moreover, male gender has been identified as 
an independent risk factor for the development of cirrhosis in patients with chronic HBV. It is 
suggested that the antifibrogenic effect of oestrogen inhibits the activation of stellate cells 
and hence reduces the process of fibrosis (Fattovich et al., 2008). Male gender was also found 
to be a risk for developing HCC with an adjusted relative risk (ARR) of 2.1 (95 CI 1.3-3.3) 
and 3.6 (95% CI 2.4-5.3) in men compared to women.(McClune and Tong, 2010). 
Throughout the world, the prevalence of HBV infection among cirrhotic patients is correlated 
with the endemicity of the virus in that area. Perz et al. estimated that the attributable 
fractions of cirrhosis due to infection with HBV ranged from 5% in regions with low 
endemicity to 57% in high endemicity regions (Perz et al., 2006). This attributable fraction 
was estimated to be 35% for states in the Eastern Mediterranean B, which includes Oman. If 
the same equation from Perz et al. is applied to our study cohort, the attributable fraction of 
cirrhosis due to HBV in Oman would be equal to 19.6%. This percentage is lower than that 
estimated by Perz et al.s’ because their estimation was based on studies from Saudi Arabia 
and Tunisia that have different HBV prevalence to Oman. Saudi Arabia was considered to be 
of high endemicity for HBV (Abdo et al., 2012b), while Tunisia is placed in the upper 
threshold of intermediate endemicity (Ezzikouri et al., 2013). Other reasons for the different 
result may be due to the differences in the methodology of the studies. Data was collected 
prospectively in the studies from Saudi Arabia and Tunisia while retrospective data collection 
was conducted in this Omani study, and the accuracy of medical notes. 
Past exposure to hepatitis B is determined by the resolution of HBsAg with or without the 
development of anti-HBs. It is asscociated with an increased mortality in patients without 
chronic liver disease (CLD) (aHR=1.29) (Jinjuvadia et al., 2013). We found in this study that 
almost one third 124 (29.6%) of our studied cohort had cleared past infection with HBV 
(HBsAg negative), of those, 77 were negative for any other viral markers (anti-HCV). When 
compared to a population of Omani blood donors, anti-HBc positivity was found in 20.5% of 
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the blood donors (Kaminski et al., 2006). The prevalence of anti-HBc is higher among 
cirrhotic patients than blood donors but the difference is not substantial. This can result from 
an over-estimation of the prevalence of anti-HBc in blood donors due to the use of one assay 
only as suggested by the authors. Conversely, HBV may not be the most important aetiology 
of cirrhosis in Oman and other factors such as HCV, alcohol and NASH need to be further 
evaluated. 
Co-infection with HBV and HCV is associated with poorer prognosis. This study revealed 
that 12.6% of this sample of cirrhotic patients had HBV and HCV co-infection. Globally, it is 
estimated that10-15% of CHB patients are co-infected with HCV (Fattovich et al., 2008).  
However, this was higher in this sample of patients as 58% of CHB patients were co-infected 
with HCV. This is because our definition of dual HCV and HBV infection was based on the 
positivity of HCV AB and anti-HBc (rather than HBsAg) (see 5.2, Interpretation of 
virological markers). Moreover, this sample is of cirrhotic patients whereas viral markers are 
expected to be higher than that of non-cirrhotic patients. The combined effect of HBV and 
HCV in causing HCC has been described in multiple international studies. A meta-analysis 
from China found that the odd ratio for developing HCC in patients positive for HBsAg and 
HCV AB (OR 35.7, 95% CI 26.2-48.5) was higher than in patients with HBsAg positive (OR 
15.6, 95% CI 11.5-21.3) or HCV AB alone (OR 8.1, 95% CI 5.0-13.0) (Shi et al., 2005). 
Furthermore, dual infection with HBV and HCV accounts for 13.78% of HCC cases in 
China. In contrast, HCV positive patients with occult HBV infection (negative HBsAg, 
positive anti-HBc and positive HBV DNA) are associated with shorter survival rate (p=0.03), 
more frequent liver related deaths (p<0.01) and higher risk of developing HCC (Squadrito et 
al., 2013). That is because the mechanism in which HBV leads to HCC is maintained in the 
occult state. 
This is the first study that has attempted to estimate the prevalence of HBV markers among 
patients diagnosed with cirrhosis in Oman. This is important because Oman is a country of 
intermediate endemicity for hepatitis B with an estimated prevalence of HBV infection of 
2%-7% in the total population. However, there has not been any research done in Oman on 
the sequalae of hepatitis B such as cirrhosis and HCC. Such estimation would outline the 
social and economic burden of hepatitis B in Oman. In view of this, prospective studies 
which look at the outcome of HBV infection in Oman need to be conducted in the future. 
These studies will help in measuring the real extent of the problem as well as evaluating the 
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role of different exposures (alcohol, metabolic syndrome, and co-infection with other viruses 
such as HCV, HDV and HIV) to the outcome of the disease. 
Prevention of HBV related complications can be achieved by primary, secondary and tertiary 
preventive strategies. Primary prevention with HBV vaccine is currently the best and most 
efficient preventive measure to reduce HBV related cirrhosis. The vaccine has been available 
since 1982. In Oman the hepatitis B vaccine was introduced Expanded Program 
Immunization in August 1990 with a reported coverage rate reaching more than 95% in 2005. 
It was also accompanied with catch-up campaigns to vaccinate school children who were 
born before that date and high risk groups. However, there is a time lag before appreciating 
the preventive effectiveness of the vaccine in reducing the burden of HBV-related hepatic 
cirrhosis and HCC. In our studied cohort, a very low fraction of patients had been vaccinated 
against HBV (5%) compared to more than a third (34%) being non-immune. We concluded 
from objective two of this thesis that most of HBV infection was acquired at a young age, 
with less frequent late horizontal transmission, so it may seem that immunizing older patients 
is not cost effective. 
 For at risk older individuals, a more selective policy is needed. Superimposed HBV infection 
in patients with CLD is associated with poorer outcomes when compared to the general 
population. Therefore, due to the high prevalence of HBV markers in patients with CLD, Lau 
and Hewlett recommended the pre-screening of CLD patients for HBsAg and anti-HBs, then 
vaccinating those negative for these markers will reduce the burden of the disease (Lau and 
Hewlett, 2005). As patients with CLD respond differently to the vaccine, Lau and Hewlett 
also recommended a post vaccination testing to assess the efficiency of the vaccine.  In 
cirrhotic patients, the response was found to be dependent on the aetiology of cirrhosis, the 
severity of the disease and the age of the patient (Roni et al., 2013). Immunogenicity of the 
HBV vaccine was better in patients with HCV related cirrhosis compared to alcohol related 
cirrhosis with a less severe stage of the disease, and in patients younger than 50 years. 
Secondary prevention of HBV related complications can be achieved with the use of anti-
viral therapy in patients chronically infected with HBV before the introduction of the vaccine. 
These drugs have been found to be effective in reducing HBV morbidity and mortality (see 
2.3.4). In Oman, treatment with lamivudine showed normalization of (ALT) in 81.8% of 
patients and reduced HBV DNA levels in 45% of patients (Dip et al., 2003).  
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Finally, once cirrhosis is established, tertiary prevention to avoid decompensating of cirrhosis 
and early detection of HCC have been developed. This can be achieved by treating HBV 
cirrhotic patients with available anti-viral therapy, and screening them for HCC. It was 
believed in the past that severe fibrosis of the liver in cirrhotic patients was irreversible. 
However, randomized controlled trials demonstrated the effectiveness of NUCs in reducing 
fibrosis and decompensation, hence, decreasing the need of liver transplant (Marcellin et al., 
2013). Treatment with these drugs is found to be safe and well tolerated. As a result, current 
guidelines indicate the treatment of patients with compensated cirrhosis when HBV DNA 
levels are higher than 2000 IU/mL regardless of ALT levels. On the other hand, patients with 
decompensated cirrhosis are recommended for treatment regardless of ALT and HBV DNA 
levels (Mutimer and Lok, 2012). 
Hepatocellular carcinoma is a major public health problem. It is the third most common cause 
of death worldwide, accounting for more than 600,000 deaths a year (Dhanasekaran et al., 
2012). Fortunately, unlike many other types of cancer, the predisposing factors are well 
recognized such as HBV, HCV and aflatoxins. HBV is estimated to account for 53% of HCC 
cases worldwide (Perz et al., 2006), with 80% occurring in cirrhotic patients (El-Serag, 
2011). This explains the highest incidence of HCC in areas where HBV is prevalent.  
Knowing the risk factors for developing HCC helps in identifying high risk groups who 
should be under surveillance programs, with the assumption that early diagnosis leads to 
better treatment outcome. The American Association for the Study of Liver Disease and the 
European Association for the Study of Liver Disease recommend screening all cirrhotic 
patients, carriers for HBV, Asian males ≥40 years, Asian females ≥ 50 years and patients 
with family history of HCC every 6-12 months (Bruix and Sherman, 2005) (2012a). This 
makes most of this group of Omani patients eligible for HCC screening. The tests most 
commonly used for surveillance purposes are US and alpha-fetoprotein (AFP). US is a non-
invasive test with no risk of radiation. It has been shown that US is effective in detecting 
HCC before clinical presentation; however, the efficacy is reduced in detecting early stages 
of HCC. Moreover, identifying small tumours is more difficult with underlying cirrhosis. 
AFP is a tumour marker for HCC. An AFP value of more than 200 or 400 ng/ml was found to 
be indicative of HCC with a 72% sensitivity, 89% specificity (Butt et al., 2012). Regardless, 
AFP is mainly used as a diagnostic rather than a surveillance test due to its suboptimal 
performance. This is because the levels of AFP are affected by the underlying disease and 
AFP is not raised in a significant proportion of tumours. There are several treatments of HCC 
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available depending on the stage of the tumour. These include surgical resection, 
transplantation, and locoregional therapy (Dhanasekaran et al., 2012).  
In conclusion, HBV markers seemed to be common among cirrhotic patients in Oman where 
more than half of the patients had evidence of past or present HBV infection. Most patients 
were of older age and male sex. This group of patients is at high risk of developing HCC and 
regular screening will aid in reducing the burden of the disease in Oman. Further research is 




6 IMPLICATIONS OF THE STUDY FINDINGS 
This work was conducted to expand our understanding of hepatitis B in Oman in two major 
domains. These are: the risk factors for HBV transmission in Omani patients and the 
contribution of the virus to liver cirrhosis. A number of implications can be derived from the 
findings of this study which are discussed below. 
In order to deal with any public health problem, the magnitude of the disease should be 
known. The estimated endemicity of hepatitis B in Oman is based on WHO calculations, 
while surveillance system shows a marked underestimation of the real burden. Therefore, a 
population-based study should be conducted to estimate the real prevalence of hepatitis B in 
Oman. Moreover, enhancing the surveillance of hepatitis B can be done in many ways. 
Firstly, as notifying HBsAg patients may be time consuming, trained staff should be available 
in all health centres to report the cases to the MoH using electronic notification methods. In 
addition, the civil number of patients should be collected to ensure the elimination of any 
duplicate cases. 
Controlling the transmission of hepatitis B in Oman can be achieved by identifying the risk 
factors associated with the transmission. In our study, we found that intrafamillial contact 
with hepatitis B positive patients and behavioural risks to be prevalent among Omani adults 
positive for HBsAg. Despite the effectiveness of universal neonatal vaccination in preventing 
vertical transmission of hepatitis B, utilising available screening programs would further 
improve the control of hepatitis B. Antenatal screening of all pregnant women should be 
implemented in MoH institutes, and greater focus on contacts screening is needed. Moreover, 
further evaluation of the impact of practices such as piercings and barber shaving is 
recommended.  
Chronic infection with hepatitis B is associated with the development of cirrhosis. We 
concluded from our study that more than half of the cirrhotic patients had a history of HBV 
infection. Anti-viral treatment of cirrhotic patients is needed to reduce risk of 
decompensation. Screening for HCC could further reduce the morbidity and mortality 
associated with hepatitis B. Further studies are needed to evaluate the effect of other 
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8  Appendix 
Hepatitis B Risk factors Questionnaire 
Hospital: Date: 
ID: Dob: 
Gender: Marital status: 
Occupation: Educational level: 
Nationality: Region: 
 
Date and place of diagnosis with HBV (e.g. blood bank, pregnancy screening test): 
Do you know why have you been referred to this hospital? 
Did you know about hepatitis B before you have been diagnosed with it? 
vaccination details (place and date): 
 
Patients’ medical history 0 1 ≥2 
Have you ever been 
hospitalized? 
   
Have you ever had any 
major surgery (e.g. 
caesarian birth, 
appendectomy) 
    
Please Specify surgery, place where conducted and date: 
Have you ever had any 
organ transplantation 
(liver or kidney) 
   
Please Specify surgery, place where conducted and date: 
Have you ever had an 
endoscopy? 
   
Please Specify surgery, place where conducted and date: 
Have you ever received 
any blood transfusion? 
   
Please Specify surgery, place where conducted and date: 
Have you ever been on 
dialysis? 
   
Do you have thalassemia or haemophilia? 
Have you ever been on 
chemotherapy treatment? 
   





Have you ever had any 
major dental treatment? 
   
 
Patients’ Social history 0 1 ≥2 
Do you have any tattoos?    
Do you have any 
piercings in your body? 
   
Where have you had it 
done? 
   
Have you ever been 
treated with phlebotomy 
(traditional)? 
   
Have you ever been 
treated with Wasam 
(cautery)? 
   
Have you ever had 
acupuncture? 
   
How often do you shave 
with a barber? 
   
Do you use syringes for 




Smoking history  Alcohol intake history  
Sexual activity  Circumcision history  
 
Is there any family history 
of HBV? 
 Please Specify 
relationship: 
 
Do you live with anyone 
who is diagnosed with 
HBV? 
 Please Specify 
relationship: 
 
Mothers’ history of HBV 
 
 
Do you live with anyone 
who is diagnosed with 
any type liver diseases 
 Please Specify 
relationship: 
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